Cardiometabolic Health Solutions With GLP-1 Therapy

Discover the impact of GLP-1 therapy on cardiometabolic health and how it can benefit individuals seeking better wellness.

Abstract: A New Paradigm in Metabolic Health

Welcome to our educational post on the revolutionary class of medications known as GLP-1 receptor agonists. As a practitioner deeply rooted in integrative and functional medicine, with a diverse background spanning chiropractic (DC), advanced practice nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), my primary goal has always been to find the most effective, evidence-based strategies to improve my patients’ health. My clinical observations at our El Paso and San Antonio clinics, coupled with the latest research, continually point toward a more integrated and holistic approach to chronic disease. This post will serve as your guide, translating complex clinical trials and physiological mechanisms into an easy-to-understand narrative. We will delve into how these powerful agents work, explore the landmark cardiovascular outcomes trials (CVOTs) that revealed their ability to protect the heart and kidneys, and differentiate among the available options, such as semaglutide (Ozempic/Wegovy) and the dual-agonist tirzepatide (Mounjaro/Zepbound). Furthermore, we will delve into the practical aspects of using these therapies, including managing side effects, understanding safety considerations, and exploring their investigational uses in everything from neuroprotection to fertility. Most importantly, we’ll connect these pharmacological advancements back to the core principles of integrative health, examining how integrative chiropractic care is essential for maximizing patient outcomes and achieving true, sustainable well-being.

Rethinking Diabetes: Beyond Glucose-Centric Care

In my years of practice, I’ve seen firsthand the devastating impact of diabetes on my patients’ lives. For decades, the management of type 2 diabetes was primarily focused on lowering blood glucose levels. However, we now understand that this is only one piece of a much larger puzzle. It’s a reality underscored by stark statistics. We know that atherosclerotic cardiovascular disease (ASCVD)—which encompasses coronary heart disease, stroke, and peripheral arterial disease—is the leading cause of death for individuals with type 2 diabetes. In fact, more than 70% of elderly patients with diabetes will likely succumb to heart disease or a stroke. The prognosis following a heart attack is significantly poorer for someone with diabetes compared to someone without, and alarmingly, these outcomes often remain bleak even when blood glucose levels are considered “well-controlled.”
This has forced a critical shift in our clinical strategy. The old model, which I call the “glucose-centric” approach, is no longer sufficient. We must move toward a multifaceted management plan that reduces overall risk. This requires a collaborative and integrative effort.

Pillars of Modern Diabetes Management

The world’s leading medical bodies, including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease Improving Global Outcomes (KDIGO) group, are all aligned on this new, comprehensive approach. It’s no longer just about the A1c. Our focus must be on:
Lifestyle Management: Foundational changes in diet and physical activity.
Diabetes Self-Management Education: Empowering patients with the knowledge to control their condition.
Cardiovascular Risk Reduction: Aggressively managing blood pressure, cholesterol (lipids), and, of course, glucose levels.
Weight Management: Addressing excess weight as a key driver of metabolic dysfunction.
Smoking Cessation: Eliminating a major accelerator of cardiovascular disease.
This holistic view is the cornerstone of effective, 21st-century care.

Clinical Case Study: The Challenge of “Over-Basalization”

To illustrate these concepts, let’s consider a case similar to many patients I see in my clinic. We’ll call her Naomi.
Naomi is a 66-year-old female who has been living with type 2 diabetes for 12 years. Despite being on a robust medication regimen, her health is not where it needs to be.
A1c: Her last A1c was 8.3%, well above the target of less than 7%.
Comorbidities: She has high cholesterol (hyperlipidemia), hypertension, and protein in her urine (proteinuria), a sign of early kidney stress.
Medications:
Metformin 1000 mg twice daily.
Degludec insulin (a basal insulin): 66 units daily.
An SGLT-2 inhibitor (a class of oral diabetes medication).
A statin for cholesterol.
An ARB for blood pressure.
Weight: She weighs 220 pounds and is 5’9 “, giving her a BMI of 32.5, placing her in the obese category.
Glucose Readings:
Her fasting glucose levels are between 140 and 160 mg/dL. The goal is typically 90-130 mg/dL.
Her postprandial (after-meal) glucose levels are 160-170 mg/dL. While the ADA goal is under 180 mg/dL, many specialists, including myself, prefer to see this number much lower, ideally under 140 mg/dL two hours after a meal.

The Problem: Over-Basalized and Still Not at Goal

Naomi’s case highlights a common clinical problem: “over-basalization.” She is taking a very high dose of basal insulin, yet her A1c and fasting glucose are still too high. A simple clinical calculation I use is to multiply a patient’s weight in kilograms by 0.5. For Naomi, who weighs 100 kg, this suggests that a basal insulin dose above 50 units may be excessive. At 66 units, she is clearly over-basalized.
The high basal insulin dose isn’t effectively controlling her blood sugar, and it’s likely contributing to her difficulty with weight management. The logical next step in a traditional model might be to add prandial (mealtime) insulin to cover her post-meal glucose spikes. However, this is where we can intervene more intelligently. Before adding more insulin, which often leads to further weight gain and increased risk of hypoglycemia, we should consider a GLP-1 receptor agonist. This approach leverages the body’s natural “incretin effect” to address the very issue Naomi is struggling with: postprandial hyperglycemia.

Understanding GLP-1 Receptor Agonists: The Incretin Effect

To truly appreciate these medications and understand why a GLP-1 agent is such a powerful tool, we need to talk about the “incretin effect.” This term describes a fascinating physiological process that is glucose-dependent, meaning these hormones act primarily when glucose is present. Our bodies naturally produce incretin hormones, specifically GLP-1 (Glucagon-Like Peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), which are synthesized and released by specialized “L-cells” in the jejunum, a part of our small intestine.
This release is triggered by the presence of food in the gut. When you eat a meal, these hormones are secreted into the bloodstream, orchestrating a multi-pronged response:
Stimulates Insulin Secretion: It signals the pancreas to increase insulin secretion, but only in a glucose-dependent manner. This means it only works when blood sugar is high, dramatically reducing the risk of hypoglycemia compared to insulin or other medications.
Suppresses Glucagon Release: It signals the pancreas to stop releasing glucagon, a hormone that prompts the liver to produce more glucose. This prevents unnecessary glucose from entering the bloodstream.
Slows Gastric Emptying: It slows down the rate at which food leaves the stomach. This makes you feel full sooner and for longer, helping to control appetite and prevent sharp, rapid spikes in blood sugar after meals.
Promotes Satiety: It acts directly on the brain to reduce appetite and increase feelings of fullness.
In individuals with type 2 diabetes, this natural incretin effect is often blunted or, in some cases, completely absent. They produce very low levels of their native GLP-1 hormone. This deficiency leads to insufficient insulin secretion after meals and a failure to suppress glucagon. The result is the hallmark hyperglycemia we see in diabetes. GLP-1 receptor agonists are medications designed to mimic the action of our own GLP-1, but they are engineered to last much longer in the body, restoring and amplifying these beneficial effects.

Mechanisms of Action: More Than Just Blood Sugar Control

The mechanisms of these drugs are multifaceted and explain not only their benefits but also their common side effects.
Gastrointestinal System: In the presence of a GLP-1 agonist, gastric emptying is significantly slowed. This delay is a primary reason patients feel full for longer, which naturally leads to reduced food intake and contributes to weight loss. Unfortunately, this slowing effect can also cause side effects like mild nausea and occasionally vomiting, especially in individuals with a history of gastroparesis. Some patients may experience diarrhea, while others report constipation or mild abdominal pain.
Central Nervous System (Brain): We believe that these small-molecule drugs can cross the blood-brain barrier and act directly on the brain’s appetite centers, such as the hypothalamus. This central action helps to decrease appetite and reduce food cravings, providing another powerful mechanism for weight loss. The feeling of prolonged satiety is likely a combination of this central effect and the delayed gastric emptying.
Pancreas: In the pancreas, GLP-1 agonists stimulate glucose-dependent insulin secretion from the beta cells. Simultaneously, they suppress glucagon secretion. By lowering glucagon, they help reduce the liver’s inappropriate production and release of stored glucose, a common dysfunction in type 2 diabetes.

The “Ominous Octet” and the Power of GLP-1s

In 2009, the renowned endocrinologist Dr. Ralph DeFronzo published a seminal paper describing the “Ominous Octet”—eight core pathophysiological defects that contribute to type 2 diabetes (DeFronzo, 2009). This framework helps us understand the complexity of the disease. What is remarkable is that GLP-1 receptor agonists address six of these eight defects very effectively. Their widespread use makes them among the most comprehensive therapies available.

Choosing the Right GLP-1 Agonist: A Comparative Look

The family of GLP-1 agents has grown, offering us a variety of options with distinct profiles. It’s crucial to choose an agent that aligns with the individual patient’s needs. Let’s look at the data from leading researchers to understand the impact of these medications. When we compare these agents, we see a clear progression in efficacy:
Liraglutide resulted in a weight loss of about 2.7 kilograms and a just under 1% reduction in HbA1c.
Dulaglutide improved upon this, showing an average weight loss of 4.6 kilograms.
Semaglutide represented a significant leap forward, demonstrating an average weight loss of 6.4 kilograms and a more robust HbA1c reduction of between 1.8% and 2.1%.
Then came tirzepatide, a dual GIP and GLP-1 receptor agonist, which has shown truly remarkable results. In clinical trials, it was associated with an average weight loss of 11.2 kilograms—almost double that of semaglutide—and an impressive 2.3% reduction in HbA1c.
It’s crucial to note that these powerful results, particularly for weight loss, were observed at the higher doses approved by the FDA during the drug approval process. Here’s a breakdown of the key players, based on the latest research and FDA indications as of May 21, 2026:
Medication (Brand Name)
Key Indications & Benefits
A1c Lowering
Typical Weight Loss
Semaglutide (Ozempic/Rybelsus)
Type 2 Diabetes, Weight Loss (Wegovy), MACE Reduction, Nephropathy Protection. Semaglutide is a potent agent with robust evidence of cardiovascular and kidney benefits.
~1.5-2.0%
~15% of body weight
Tirzepatide (Mounjaro/Zepbound)
Type 2 Diabetes, Weight Loss, OSA. This is a “twincretin,” a dual GLP-1/GIP agonist, showing the highest efficacy for both glucose lowering and weight loss. Cardiovascular outcome trials are ongoing but look promising.
>2.0%
>20% of body weight
Dulaglutide (Trulicity)
Type 2 Diabetes, MACE Reduction, Nephropathy Protection. A reliable weekly injection with proven cardiovascular and kidney benefits, though with more moderate weight loss compared to newer agents.
~1.0-1.5%
~3-5 kg
Liraglutide (Victoza)
Type 2 Diabetes, MACE Reduction, Nephropathy Protection. One of the first GLP-1s with proven cardiovascular benefits, but it requires a daily injection. Weight loss is more modest. A higher dose is available for weight loss (Saxenda).
~1.1%
~2.5 kg
Exenatide (Byetta/Bydureon)
Type 2 Diabetes. One of the earliest GLP-1s. It is effective for glucose control but has less impact on weight and lacks the proven cardiovascular protection of newer agents.
<1.0%
~2.9 kg
MACE = Major Adverse Cardiovascular Events (heart attack, stroke, cardiovascular death). OSA = Obstructive Sleep Apnea.

When I select a GLP-1 agonist for a patient, I’m not just looking at the A1c. For Naomi, who has hypertension and proteinuria, choosing an agent with proven MACE reduction and nephropathy protection like semaglutide (Ozempic) or dulaglutide (Trulicity) would be a critical part of a comprehensive strategy. Given her significant need for weight loss and A1c reduction, semaglutide or tirzepatide would be the top consideration.

Cardiovascular Outcomes Trials (CVOTs): The Game-Changer

The history of diabetes medications is marked by a pivotal moment in 2008. Following safety concerns with earlier drugs, the FDA mandated that all new diabetes drugs undergo large, long-term Cardiovascular Outcomes Trials (CVOTs). The goal was to demonstrate that these new drugs did not harm the cardiovascular system.
What happened next was completely unexpected and revolutionized our field. Not only were these drugs safe, but they also provided robust cardiovascular risk reduction. This discovery shifted the paradigm from “just diabetes drugs” to essential tools for cardiologists and nephrologists. The GLP-1 receptor agonists soon followed with their own impressive CVOT data:
REWIND Trial (Dulaglutide): Showed a 12% reduction in major adverse cardiovascular events (MACE).
LEADER Trial (Liraglutide): Showed a 13% reduction in MACE.
SUSTAIN-6 Trial (Subcutaneous Semaglutide): Showed a remarkable 26% reduction in MACE.
These large, multi-year, double-blind, placebo-controlled studies involving thousands of patients solidified the role of these medications as cornerstones of cardio-renal-metabolic care. We now view metabolic disease through the lens of the cardio-renal-metabolic (CRM) triad. These systems are bidirectionally linked; a problem in one inevitably affects the others.

How Professional Guidelines Position GLP-1 Agonists

The American Diabetes Association (ADA) has recognized the profound benefits of these medications. The 2025 ADA guidelines, published annually in Diabetes Care, place a strong emphasis on GLP-1 receptor agonists, especially for certain patient populations (ElSayed et al., 2024).
The ADA treatment algorithm is divided into two main pathways:
The Left-Hand Pathway: For patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), or those at very high risk. For these patients, a GLP-1 receptor agonist is now strongly favored as a primary agent, sometimes even before metformin.
The Right-Hand Pathway: For patients whose primary needs are glycemic control and weight management but who do not have the high-risk cardiovascular or kidney profile.
For patients with CKD, SGLT2 inhibitors are often the first choice. However, certain GLP-1 agonists, specifically semaglutide, have also earned an indication for kidney protection. The FLOW trial, stopped early due to overwhelmingly positive results, demonstrated that semaglutide reduced the risk of major kidney disease events and cardiovascular death by 24% in people with type 2 diabetes and CKD.

Balancing Body and Metabolism- Video

Navigating the Switch: A Guide to Changing GLP-1 Agonists

As a clinician committed to patient-centered care, I often encounter scenarios in which a medication switch is considered. A recent case involved a patient, we’ll call her Tammy, who was on Trulicity (dulaglutide) but wasn’t achieving her desired weight loss. Through shared decision-making, we explored a switch. This requires a careful, evidence-informed approach.
Switching from Trulicity (dulaglutide) to Ozempic (semaglutide): To switch from a 1.5 mg dose of dulaglutide, I would begin her on semaglutide 0.5 mg weekly. This conservative start minimizes side effects. After a month, if she tolerates it well, we could increase her to a weekly dose of 1 mg.
Switching from Trulicity (dulaglutide) to Mounjaro (tirzepatide): After her last dose of Trulicity, we would wait a full week (a “washout” period) before starting tirzepatide. I would initiate treatment with tirzepatide 5 mg weekly. The goal is to find the optimal dose—the one where the patient achieves significant satiety and weight loss with minimal side effects—by titrating up every four weeks if needed.

The Expanding Universe of GLP-1 Receptor Agonists

The story of GLP-1 agonists is no longer confined to diabetes. The research community is buzzing with discoveries about their far-reaching benefits.

Metabolically Associated Steatotic Liver Disease (MASLD)

One of the most promising frontiers is in liver health. The primary benefit for MASLD and its inflammatory progression, MASH, comes from the significant and sustained weight loss these drugs induce, which directly decreases fat deposition in the liver (Abbasi, 2024). Novo Nordisk is seeking FDA approval for this indication, which we may see by late 2025 or early 2026.

Expanding Indications: Beyond Diabetes

The benefits have proven to extend beyond patients with type 2 diabetes, as established by two landmark trials:
STEP-HFpEF Trial: This study showed that in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide led to significant improvements in heart failure symptoms and physical limitations, regardless of whether the patients had diabetes (Kosiborod et al., 2023).
SELECT Trial: This trial involved over 17,000 overweight or obese patients with pre-existing heart disease but without diabetes. The group receiving semaglutide showed a 20% reduction in MACE compared to placebo.

Cravings, Compulsive Behaviors, and Addiction

A consistent report from my own patients is a dramatic reduction in cravings. They describe it as a quieting of the constant “food noise” in their brain, with a decreased desire for alcohol and smoking. This points to a fundamental impact on the brain’s reward pathways.

PCOS, Fertility, and the “Ozempic Babies” Phenomenon

For many women with Polycystic Ovary Syndrome (PCOS), the substantial weight loss from these drugs can restore metabolic balance and regulate menstrual cycles. This has led to enhanced fertility and the recent media phenomenon of “Ozempic babies.”

Other Investigational Uses

Researchers are also observing positive effects in:
Neuroprotection: Patients with dementia and Parkinson’s disease have shown a stall in disease progression, suggesting a neuroprotective effect within the brain.
Latent Autoimmune Diabetes in Adults (LADA): The off-label use of GLP-1 agonists is being studied to help preserve remaining beta-cell function in this form of autoimmune diabetes (Buzzetti et al., 2020).
Respiratory Health: In patients with asthma and COPD, these drugs have been associated with fewer exacerbations, likely due to their anti-inflammatory properties.

The Role of Integrative Chiropractic Care

This is where my perspective as a DC, APRN, and Functional Medicine Practitioner becomes so important. While these medications are incredibly powerful, they are tools, not cures. True, lasting health is achieved when we combine these advanced pharmacotherapies with a foundation of lifestyle and structural wellness.
Optimizing Nervous System Function: The nervous system is the body’s master controller. The gut-brain axis is a two-way communication highway critical for satiety signaling. Chiropractic adjustments can help reduce nerve interference, potentially enhancing the body’s response to these signals and improving the efficiency of the gut-brain connection.
Supporting Musculoskeletal Health During Weight Loss: Rapid and significant weight loss can place new stresses on the body as a patient’s center of gravity shifts. This can lead to new patterns of musculoskeletal pain. Integrative chiropractic care is crucial for managing these biomechanical changes through targeted adjustments, soft-tissue work, and the prescription of corrective exercises.
Addressing the Root Causes: Functional medicine teaches us to ask “Why?” We use a holistic approach to craft personalized nutrition plans, develop sustainable exercise regimens that preserve muscle mass, and implement stress-management techniques to reduce cortisol levels.
Chiropractic care is not an alternative to these medications; it is a vital complement. By ensuring the body’s structure and nervous system function optimally, we create an environment in which these powerful drugs can work most effectively.

Safety, Side Effects, and Practical Recommendations

While transformative, these medications require careful management.

Common GI Side Effects

Nausea: This is the most common side effect, often linked to early satiety.
Constipation or Diarrhea: The effect on motility varies by individual.
Management Strategy: The key is to “start low and go slow.” I start patients on the lowest possible dose for at least a month before considering an increase.

Important Safety Issues

Gallbladder Events: Rapid weight loss can increase the risk of gallstones.
Acute Kidney Injury: Can occur from severe nausea and vomiting leading to dehydration. Staying well-hydrated is critical.
Pancreatitis: Though rare, patients with severe, persistent abdominal pain should seek immediate medical attention.
Surgical Considerations: Anesthesiology guidelines recommend stopping weekly GLP-1 agonists at least one to two weeks before a planned surgery to reduce the risk of aspirating stomach contents.
Muscle and Bone Mass: Significant weight loss involves some loss of lean muscle and bone. I work with patients to incorporate resistance training and ensure adequate protein intake.

Black Box Warning: Thyroid C-Cell Tumors

These medications carry a black box warning regarding the risk of thyroid C-cell tumors observed in rodent studies. While this link has not been established in humans, the drugs are contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Final Thoughts: A New Hope for Patients

The advent of modern GLP-1 receptor agonists has fundamentally changed the landscape of diabetes and metabolic care. For patients like Naomi, starting a GLP-1 agonist is not just about adding another medication; it’s about shifting her disease trajectory. It offers the potential to achieve her A1c goal, lose significant weight, reduce her reliance on insulin, and lower her risk of a future heart attack or stroke.
As healthcare providers, it is our responsibility to embrace a comprehensive, integrative approach. By combining the power of these advanced medications with the foundational principles of lifestyle medicine and chiropractic care, we can offer our patients a new level of hope and empower them to achieve a healthier, more vibrant future.

References

SEO Tags: GLP-1 agonists, Semaglutide, Tirzepatide, Ozempic, Mounjaro, Wegovy, Zepbound, Type 2 Diabetes, Weight Loss, Cardiovascular Risk Reduction, Integrative Chiropractic Care, Functional Medicine, Dr. Alexander Jimenez, El Paso Chiropractor, A1c, Postprandial Glucose, Incretin Effect, Metabolic Health, Heart Health, Kidney Disease, CVOT, Ominous Octet, Gastric Emptying, Satiety, MASH, neuroprotection, PCOS, fertility, LADA, patient-centered care, cardio-renal-metabolic health, chiropractic adjustment, musculoskeletal health

May 21, 2026

GLP-1 Receptor Agonist Insights for Metabolic Health

Understand how GLP-1 receptor agonists for metabolic health can enhance your lifestyle and support metabolic function effectively.

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the evolution, mechanisms, clinical evidence, safety considerations, perioperative care, drug interactions, and practical, long-term use of GLP-1 receptor agonists and the dual GLP-1/GIP agent tirzepatide. Drawing from landmark trials and consensus statements, I explain how these therapies improve weight, glycemia, cardiovascular, and kidney outcomes, why side effects occur, and how to prevent discontinuation. I show how integrative chiropractic care enhances autonomic balance, mitigates pain, preserves lean mass, and supports gastrointestinal tolerance—turning pharmacology into durable, whole-person improvement. You will learn when to choose each agent, how to titrate safely, how to personalize plans for special populations, and how to weave together resistance training, nutrition, breathwork, sleep, and manual therapy for sustained results. I close with clinical observations from my practice to help translate research into patient-centered care.

Why GLP-1 Therapies Matter Now for Obesity and Cardiometabolic Health

Obesity affects over 40% of U.S. adults and drives risk for type 2 diabetes, cardiovascular disease, chronic kidney disease, sleep apnea, osteoarthritis, and several cancers. When lifestyle alone is not enough, modern incretin-based therapies provide high-impact, evidence-backed tools to reduce caloric intake, improve glycemic control, and lower cardiometabolic risk.

GLP-1 receptor agonists have become first-line agents in diabetes care and are increasingly central to chronic weight management due to their robust effects on A1C and weight.
Dual agonists like tirzepatide amplify effects by engaging GIP alongside GLP-1, often resulting in greater weight loss and improved glycemic control.
Integrative practice models—combining chiropractic care, movement, nutrition, and behavioral strategies—help patients maintain function, preserve lean mass, and translate weight loss into daily-life gains.

My goal is simple: equip you to use these therapies confidently and safely, while integrating musculoskeletal and autonomic strategies that make results stick.

Key Terminology and Why These Hormones Matter

GLP-1 receptor agonists: Medications that activate the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon, slowing gastric emptying, reducing appetite, and modulating reward circuits. Examples: exenatide, liraglutide, dulaglutide, semaglutide.
GIP (glucose-dependent insulinotropic polypeptide): An incretin that enhances insulin secretion; co-agonists that stimulate GIP and GLP-1 receptors (e.g., tirzepatide) can produce synergistic metabolic effects.
Glucagon (GCG): Beyond counter-regulating insulin, glucagon influences hepatic glucose output, energy balance, and lipid metabolism. Triple agonists (GLP-1/GIP/glucagon) aim to increase energy expenditure and fat oxidation.
Nutrient-stimulated hormone therapies (NUSH): An umbrella for therapies mimicking endogenous gut-hormone responses to food, including GLP-1 and GIP agents.

These terms frame how incretin therapies act across multiple organ systems to deliver outcomes that matter: improved glycemia, reduced appetite, lower weight, and protection for the heart and kidneys.

Mechanisms of Action: The Physiology Behind the Benefits

GLP-1 receptors are widely expressed. Their distribution explains the breadth of clinical benefits and guides how we anticipate and manage effects.

Pancreas
- Beta cells: GLP-1 signaling raises cAMP and activates PKA/Epac, leading to glucose-dependent insulin secretion. Because secretion is tied to ambient glucose levels, these agents have a lower risk of hypoglycemia than non–glucose-dependent secretagogues. Chronic signaling may support beta-cell survival in preclinical models, potentially slowing decline.
- Alpha cells: GLP-1 suppresses inappropriate glucagon release during hyperglycemia, reducing hepatic gluconeogenesis and glycogenolysis, thereby improving fasting and postprandial glycemia.
Gastrointestinal Tract
- Gastric emptying: GLP-1 slows gastric emptying through vagal and enteric pathways, reducing the rate of glucose appearance and increasing early satiety. Clinically, this lowers postprandial glucose spikes and reduces caloric intake.
- Satiety signaling: Gut-brain communication via vagal afferents and hindbrain nuclei enhances fullness and reduces meal size.
Central Nervous System
- Hypothalamus: GLP-1 acts on the arcuate and paraventricular nuclei, modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neurons to reduce appetite.
- Reward circuitry: Activity in the ventral tegmental area and nucleus accumbens is attenuated, blunting the dopamine reward response to hyperpalatable foods. Patients often describe reduced “food noise,” helping sustain dietary changes.
Cardiovascular and Renal Systems
- Endothelium and vasculature: GLP-1 signaling improves endothelial function, reduces inflammation and oxidative stress, and may modulate blood pressure via natriuresis.
- Kidney: GLP-1 agents reduce albuminuria and slow eGFR decline in at-risk populations via hemodynamic and anti-inflammatory mechanisms.

Why this matters: When we lower A1C without frequent hypoglycemia, patients feel and function better. Appetite suppression paired with slower gastric emptying reduces energy intake. Reward-circuit modulation tackles binge and late-night cravings. Cardio-renal protection delivers benefits beyond weight and glucose.

From Lizard Peptides to Long-Acting Analogs: The Trajectory of Innovation

Early discovery: Incretin biology matured in the 1980s, with the identification of GLP-1 and GIP as nutrient-responsive hormones.
First-to-market: Exenatide (Byetta), modeled on exendin-4 from Gila monster saliva, launched in 2005—an early example of nature-inspired pharmacology.
Human analogs and weekly dosing: Liraglutide (2009) and later extended-release exenatide (2012) improved convenience and adherence.
Semaglutide era: Weekly semaglutide (2017; oral formulation in 2019) advanced A1C and weight outcomes and earned chronic weight management approval as Wegovy (2021).
Dual agonism: Tirzepatide (2022) combined activation of the GIP and GLP-1 receptors, achieving unprecedented weight and glycemic outcomes.
What’s next: Development includes triple agonists, monthly injectables, longer-acting oral agents, and combinations with amylin analogs to optimize tolerability, efficacy, and adherence.

Evidence Highlights: What the Strongest Trials Show

Weight and Glycemic Control
- Liraglutide SCALE: ~8% mean weight loss at 56 weeks with improved cardiometabolic markers (Pi-Sunyer et al., 2015).
- Semaglutide STEP:
  - STEP 1: ~15% mean weight loss at 68 weeks in adults with overweight/obesity (Wilding et al., 2021).
  - STEP 2: ~9.6% mean weight loss with A1C reductions of ~1.6–2.0% in type 2 diabetes (Davies et al., 2021).
  - STEP 5: >13% mean weight loss beyond one year, supporting durability (Rubino et al., 2022).
- Tirzepatide SURMOUNT: 15–20% mean weight loss at 72 weeks; some cohorts approach ~25% (Jastreboff et al., 2022; Frias et al., 2023).
Cardiovascular and Renal Outcomes
- Semaglutide SELECT: ~20% reduction in 3-point MACE in adults with obesity and established cardiovascular disease but without diabetes—hard cardiovascular benefits in a non-diabetic population (Nissen et al., 2023).
- HFpEF with obesity: Semaglutide improved heart failure symptoms, physical limitations, and exercise capacity (Kitzman et al., 2023).
- Kidney outcomes: Semaglutide reduced a composite kidney outcome by ~22% among patients with obesity and cardiovascular disease (Mann et al., 2021).

In practice, I align therapy with top patient goals—glycemia, weight, heart/kidney protection—and pair medication with structured nutrition and resistance training to preserve lean mass and function.

Safety Profile: Adverse Effects and How to Mitigate Them

Early gastrointestinal effects reflect pharmacodynamic changes (delayed gastric emptying, central satiety) and typically improve with slow titration.

Common effects
- Nausea, vomiting, diarrhea, abdominal discomfort, dyspepsia, decreased appetite.
- Taste changes or aversion to fried/greasy foods
Less common but important
- Gastroparesis or bowel obstruction risk in those with severe baseline dysmotility
- Pancreatitis: monitor for persistent severe upper abdominal pain radiating to the back
- Gallbladder disease: cholelithiasis/cholecystitis risk during rapid weight loss
- Acute kidney injury: dehydration from vomiting; protect hydration and monitor renal function
- Hypoglycemia: mainly with concurrent insulin or sulfonylureas; proactively reduce doses
- Diabetic retinopathy: rapid A1C drops can transiently worsen retinopathy; coordinate care
- Body composition: risk of lean mass loss; prioritize protein and resistance training
Contraindications and boxed warning
- Thyroid C-cell tumors: contraindicated with personal/family history of MTC or MEN2
- Avoid in severe GI disease, history of pancreatitis, pregnancy, or breastfeeding.
Patient counseling essentials
- Explain theoretical thyroid risk and symptoms (neck mass, dysphagia, hoarseness, dyspnea)
- Routine calcitonin or thyroid ultrasound screening is not recommended in asymptomatic users.
- Avoid compounded products; stick to FDA-approved medications dispensed by licensed pharmacies.

Dosing Strategies: Why “Start Low, Go Slow” Works

The biology is clear: early GI symptoms represent intended effects on gastric emptying and satiety. The nervous system adapts over weeks. We protect adherence by moving at the body’s pace.

Begin at the lowest dose and extend titration steps if moderate nausea or early satiety interferes with intake.
Encourage small, protein-forward meals; limit high-fat, fried, and very sweet foods, which can exacerbate nausea.
Promote hydration and electrolytes, especially during the first 8–12 weeks.
Pair with resistance training immediately to signal lean mass retention.
If adding to insulin or sulfonylureas, proactively reduce those agents and monitor with CGM when available.

Perioperative Care: GLP-1 Use and Aspiration Risk

Consensus statements from anesthesiology and gastroenterology groups (2024) indicate that most patients can continue GLP-1 therapy before procedures. For high GI risk (marked nausea, vomiting, gastroparesis), a pre-procedural liquid diet mitigates aspiration risk.

Ask specifically about GLP-1 use during pre-op assessments.
Screen for GI symptoms and gastroparesis.
Coordinate with anesthesia on individualized liquid diet plans and NPO timing.
Resume standard dosing post-operatively once oral intake and hydration normalize.

Delaying gastric emptying is part of how these drugs work; perioperative plans must respect this physiology while balancing airway safety.

Major Drug Interactions Clinicians Must Check

Insulin and Sulfonylureas
- Risk: additive hypoglycemia
- Strategy: proactively reduce doses, monitor SMBG/CGM
Narrow Therapeutic Index Drugs
- Mechanism: delayed gastric emptying can alter absorption
- Examples: certain antiepileptics, warfarin (monitor INR), select immunosuppressants
- Strategy: intensified monitoring during initiation/up-titration; adjust timing or formulation
Tirzepatide and Oral Contraceptives
- Guidance: Use non-oral contraception for 4 weeks after initiation and each dose escalation
DPP-4 inhibitors
- Evidence: combining DPP-4 inhibitors with GLP-1 agonists adds side effects without benefit; avoid combination per ADA guidance

Public Health Safety: Counterfeit and Unregulated Online Sales

Counterfeit or “research use only” GLP-1 products marketed online pose serious risks: contamination, mislabeled doses, or entirely different compounds. Dosing errors can trigger severe GI events, dehydration, or destabilize glycemia.

Educate patients to use only FDA-approved medications via licensed pharmacies.
Verify NDC codes, lot numbers, and pharmacy licensure.
Document counseling and sourcing verification.

In my clinics, atypical adverse reactions have resolved once verified formulations were used.

FDA Safety Monitoring: Suicidal Ideation Reports Under Evaluation

In 2024, the FDA began evaluating reports of suicidal ideation among users of GLP-1 agents and tirzepatide. No causal link has been established, but vigilance is appropriate.

Baseline screening for mood, suicidality, and eating disorders
Repeat checks after each dose escalation and at quarterly maintenance visits
Collaborate with behavioral health; protect sleep and circadian regularity

Appetite suppression and rapid weight change intersect with mood pathways; proactive monitoring supports safety and adherence.

Long-Term Use: Why Continuing Therapy Matters

Obesity is a chronic, relapsing disease with hypothalamic set points, adipocyte signaling, and metabolic adaptation. Discontinuation often leads to a regain.

STEP 1 extension: After discontinuing semaglutide, participants regained roughly two-thirds of the weight lost at one year (Rubino et al., 2022).
SURMOUNT-4: Continuing tirzepatide maintained losses; switching to placebo led to ~14% weight regain by week 52 (Jastreboff et al., 2023).

Interpretation: Long-term pharmacotherapy—such as antihypertensives—helps maintain gains in weight, glycemia, and risk reduction. Maintenance plan.

Discontinuation: Why Patients Stop and How to Prevent It

Real-world discontinuation can be high in the first year. Top drivers include adverse effects, cost, access gaps, and unmet expectations.

Start low, go slow; hold dose increases when symptoms arise.
Front-load education on expected GI effects and management strategies.
Build multidisciplinary support: dietitians, pharmacists, behavioral health, and integrative clinicians.
Offer coverage, navigation, and consider manufacturer assistance.

Adherence is a physiologic outcome—patients stay the course when symptoms are managed, costs are addressed, and goals feel meaningful.

Guideline Alignment: Where GLP-1 Therapies Fit

Diabetes (ADA, AACE): Recommend GLP-1 receptor agonists for patients with type 2 diabetes who have or are at high risk for ASCVD, CKD, HF, obesity, or MASLD. Focus on cardiometabolic risk beyond A1C (American Diabetes Association, 2024; American Association of Clinical Endocrinology, 2023).
Obesity (ACC): GLP-1 agents are first-line pharmacotherapy for weight management without requiring lifestyle “failure,” given their superior efficacy compared with lifestyle alone and a lower risk than bariatric surgery for many patients (American College of Cardiology, 2024).

Personalizing Therapy: Matching the Agent to the Patient

Type 2 diabetes with ASCVD: Favor agents with proven MACE reduction (e.g., semaglutide); coordinate with cardiology.
CKD or albuminuria: GLP-1 RAs offer renal benefits; monitor eGFR; consider SGLT2 inhibitors for additive renal/HF protection.
History of gallbladder disease: Titrate slowly, promote steady calorie deficits, and monitor biliary symptoms.
GI motility concerns: Avoid or use extreme caution with baseline gastroparesis.
Reproductive planning: Avoid during pregnancy and breastfeeding; counsel on contraception; with tirzepatide, avoid oral contraceptives during initiation and dose escalations.
Co-therapy with insulin/sulfonylureas: Reduce doses and use CGM to minimize hypoglycemia.

Integrative Chiropractic Care: Amplifying Outcomes and Preserving Function

As a clinician working at the intersection of neuromusculoskeletal medicine and metabolic health, I integrate chiropractic modalities alongside GLP-1 therapy to improve adherence, comfort, and functional capacity.

Chiropractic and neuromusculoskeletal support
- Spinal and extremity adjustments optimize joint mechanics and reduce nociceptive drive, making early exercise more comfortable. Less pain improves sleep and autonomic balance, which supports glycemic control and fat loss.
- Soft-tissue therapies and myofascial release address compensations and movement restrictions that can worsen with rapid weight change, improving range of motion and exercise tolerance.
- Neurodynamic and proprioceptive training enhance motor control and balance, enabling safe progression to resistance training, which is essential for preserving lean mass.
Exercise and body composition
- Focus on progressive resistance training (2–4 sessions/week) with compound movements; phase in isometrics and closed-chain exercises when pain or mobility limits exist.
- Build Zone 2 aerobic base to support mitochondrial health, insulin sensitivity, and recovery without driving excessive hunger.
- Track functional benchmarks (sit-to-stand reps, loaded carries, gait speed) to reinforce adherence.
Nutrition and recovery
- Protein-first meals: Target 1.2–1.6 g/kg/day to preserve lean mass and mitigate hunger variability; use protein shakes or Greek yogurt plus electrolytes when appetite is low.
- Emphasize micronutrient density: potassium, magnesium, and omega-3s to support cardiometabolic health and reduce cramping.
- Meal pacing aligns with delayed gastric emptying and reduces the risk of nausea.
Autonomic regulation and behavior
- Diaphragmatic breathing and brief HRV-guided practices before meals improve GI comfort and reduce stress-eating triggers.
- Sleep optimization helps stabilize hunger hormones (ghrelin and leptin) and improves glucose control.
- Cognitive-behavioral frameworks help patients leverage reduced food noise and build new routines.

Physiologic coherence: Pain reduction lowers sympathetic drive; movement sends mechanotransduction signals to muscle and bone; autonomic balance enhances vagal inputs that support gastric motility and satiety. Integrative care makes GLP-1 therapy more tolerable and more effective.

Clinical Observations from My Practice

From my work shared at Chiromed.com and my professional collaborations:

Initiating GLP-1 therapy alongside structured resistance training and pain-modulating manual care reduces fatigue and improves willingness to train, protecting lean mass and posture during weight loss.
Neck and low-back discomfort may transiently flare as body mass redistributes; timely adjustments and soft-tissue work smooth transitions and prevent activity drop-off.
Simple breathwork before meals reduces GI complaints and improves pacing, suggesting autonomic co-regulation complements delayed gastric emptying.
The most durable changes occur when we measure function—gait speed, grip strength, sit-to-stand improvements—rather than focusing only on the scale.

For more of my clinical insights and interprofessional collaborations, visit:

Case Study: Re-Initiating Semaglutide Safely After an Interruption

Patient: Amanda Chen, 58, T2D, BMI 36, osteoarthritis. Previously tolerated semaglutide at 1.7 mg weekly, lost 12 lbs, then paused therapy for six weeks due to GI illness. She wants to restart at 1.7 mg.
Clinical reasoning: Even after prior tolerance, restarting at a high dose post-gap increases the risk of GI side effects due to resetting of gastric emptying and gut–brain signaling.
Best practice:

Restart at 0.25 mg weekly for 4 weeks, then re-titrate per standard protocol:
- 0.25 mg weekly × 4 weeks
- 0.5 mg weekly × 4 weeks
- 1.0 mg weekly × 4 weeks
- 1.7 mg weekly × 4 weeks (if indicated for weight)
- 2.4 mg weekly (target for obesity indications), pacing individualized
If adverse effects occur: pause escalation; maintain dose longer until tolerance improves.

Monitoring:

During titration: monthly visits to assess GI effects, hydration, weight change, glycemia, blood pressure, and adherence.
Maintenance: quarterly follow-up; more frequent if combining with insulin or in older adults with CKD risk.

Safety parameters:

Glycemia: SMBG/CGM; reduce insulin/sulfonylurea doses to prevent hypoglycemia.
Renal: serum creatinine/eGFR; ensure hydration, especially if vomiting/diarrhea or diuretic use.
Pancreatitis: persistent upper abdominal pain and vomiting; check lipase promptly.
Gallbladder: RUQ pain; consider ultrasound if symptomatic.
Thyroid/MTC risk: screen personal/family history for MEN2/MTC.
Mental health: mood checks and suicidality screening during escalations and milestones.

Counseling for GI tolerance:

Hydration: 2–3 liters/day unless contraindicated; separate fluids from meals if reflux is prominent.
Meal structure: smaller, protein-forward, nutrient-dense meals; avoid large, high-fat/fried meals early.
Triggers: limit carbonation and alcohol; avoid lying down after meals.
Constipation plan: fiber, magnesium citrate or osmotic laxatives as needed, daily walking.
Nausea strategies: ginger tea, cooled foods, bland starters; consider dose holds rather than reductions when symptoms are transient.
Expectations: normalize mild GI effects; reinforce adherence.

Adaptations:

Low responders (<5% weight loss at 12–16 weeks): verify adherence, timing, nutrition, sleep; consider longer holds at intermediate doses or switching agents if the maximally tolerated dose yields inadequate response.
Excessive responders (frailty, BMI <18.5, low protein intake): evaluate for endocrinopathies, malabsorption, or disordered eating; reduce dose or pause; engage dietitian and behavioral health.

Eating Right to Feel Better- Video

Integrative Nutrition: The MEAL Framework

Nutrition is integral to efficacy and safety; I use the MEAL framework:

M: Muscle maintenance
- Set protein targets at 1.2–1.6 g/kg/day to preserve lean mass.
- Pair with resistance training to counter sarcopenia and sustain resting metabolic rate.
E: Energy balance
- Align caloric intake with satiety cues; maintain micronutrient sufficiency.
- Spread intake throughout the day to stabilize energy and blood glucose levels.
A: Avoid side effects
- Constipation: fiber, fluids, magnesium, or PEG as needed, daily movement.
- Nausea/GERD: small portions, low-fat cooking, avoid carbonation and late meals; consider short-term H2 blockers or PPIs when necessary.
L: Liquid intake
- 2–3 liters/day supports motility and reduces dizziness/fatigue from reduced intake; add electrolytes with physical activity or heat exposure.

Movement and Resistance Training: Protecting Lean Mass and Metabolic Rate

Exercise prescriptions should be specific and progressive:

Aerobic baseline: build toward 150 minutes/week moderate intensity or 75 minutes/week vigorous.
Resistance training: 60–90 minutes/week over 2–3 sessions to stimulate muscle protein synthesis.
Daily movement: 30–60 minutes of light-to-moderate activity supports glycemic control and GI motility.
Balance and mobility are essential in older adults; they reduce fall risk and support independence.
Functional measures: grip strength and 6-minute walk tests track resilience and guide load.

This protects lean mass, stabilizes metabolism, and makes pharmacologic weight loss translate into better function.

Practical Clinical Pearls: What Works Best

Start with the why: match therapy choice to indications—T2D, obesity, ASCVD risk, CKD, MASLD—and articulate goals beyond A1C.
Dosing discipline: start low, go slow; hold at a dose rather than escalate into intolerance.
Education first: teach injection technique, site rotation, and what to expect in the first 4–8 weeks.
Prevent hypoglycemia: down-titrate insulin or sulfonylureas; use CGM when available.
Watch gallbladder and pancreas: RUQ pain or persistent nausea warrants evaluation; check lipase and consider ultrasound.
Renal protection: monitor eGFR, especially if vomiting or diuretic use is present; emphasize hydration.
Reproductive safety: avoid in pregnancy and lactation; counsel on contraception. With tirzepatide, avoid oral contraceptives for 4 weeks after start/escalation.
Thyroid precautions: screen for MTC/MEN2 history; discuss boxed warning implications.
Expectation management: set a realistic pace for weight loss; focus outcomes on function, labs, and cardiometabolic risk.
Team-based care: dietitians, diabetes educators, pharmacists, behavioral health, and integrative clinicians raise success and reduce discontinuation.

Common Pitfalls to Avoid

Rapid escalation: rushing doses leads to dropout; titration patience preserves adherence.
Insufficient counseling: early discontinuation is preventable with anticipatory guidance.
Overlooking interactions: reassess narrow-therapeutic-index drugs, insulin/sulfonylurea dosing, and contraception with tirzepatide.
Hydration gaps: many symptoms improve with fluids and electrolytes; formalize targets.
Missing pancreatitis signals: persistent or escalating abdominal pain deserves prompt workup.
Skipping thyroid/MEN2 screening: maintain vigilance given labeled risks.
Scale-only thinking: anchor goals in function, labs, and risk, not just pounds.
Cost surprises: verify coverage, explore assistance, plan contingencies.
Social determinants: address food access, transportation, and home stability.
Set-and-forget: active monitoring is essential during the first 3–6 months and after dose changes.

Putting It All Together: A Patient-Centered, Integrative Roadmap

Verify medication source; prescribe only FDA-approved products via licensed pharmacies.
Screen for mood/eating disorders, pancreatitis/gallbladder risks, MEN2/MTC history.
Plan insulin/sulfonylurea reductions, CGM/SMBG, hydration, and nutrition strategies.
Initiate semaglutide at 0.25 mg weekly for 4 weeks; escalate only when tolerated.
Build a nutrition plan using the MEAL framework with protein targets and micronutrient sufficiency.
Prescribe movement: progressive aerobic minutes, resistance training 2–3 days/week, plus balance and mobility.
Integrate chiropractic care for autonomic regulation, pain control, and kinetic chain optimization.
Schedule monthly check-ins during titration; quarterly thereafter; more frequent if medically complex.
Prepare for surgery by collaborating with anesthesia; use liquid diet protocols for high-risk cases.
Reassess response at 12–16 weeks; adapt the dose or switch agents as needed; always align with patient goals and values.

By weaving together pharmacology, lifestyle medicine, and integrative chiropractic strategies, we make GLP-1 therapies safer, more tolerable, and longer-lasting—delivering the cardiometabolic benefits patients deserve while preserving function and quality of life.

References

SCALE Obesity and Prediabetes: efficacy of liraglutide for weight management (Pi-Sunyer, F. X., et al., 2015). New England Journal of Medicine.
STEP 1: semaglutide for weight management in adults with obesity (Wilding, J. P. H., et al., 2021). New England Journal of Medicine.
STEP 2: semaglutide in type 2 diabetes with overweight/obesity (Davies, M. et al., 2021). The Lancet.
STEP 5: Two-year effects of semaglutide on weight loss (Rubino, D. M., et al., 2022). Nature Medicine.
SURMOUNT-1: tirzepatide in adults with obesity (Jastreboff, A. M., et al., 2022). New England Journal of Medicine.
SURMOUNT-2: tirzepatide in adults with type 2 diabetes and obesity (Frias, J. P., et al., 2023). The Lancet.
SELECT: semaglutide and cardiovascular outcomes in patients with overweight/obesity without diabetes (Nissen, S. E., et al., 2023). New England Journal of Medicine.
Semaglutide in heart failure with preserved ejection fraction and obesity (Kitzman, D. W., et al., 2023). New England Journal of Medicine.
Effects of GLP-1 receptor agonists on kidney outcomes (Mann, J. F. E., et al., 2021). The Lancet.
FDA communication on compounded GLP-1 products and safety concerns (U.S. Food and Drug Administration, 2023).
American Diabetes Association Standards of Medical Care in Diabetes—2024 (American Diabetes Association, 2024). Diabetes Care.
American Association of Clinical Endocrinology Pharmacotherapy Guidelines (American Association of Clinical Endocrinology, 2023). Endocrine Practice.
American College of Cardiology Obesity Pharmacotherapy Consensus (American College of Cardiology, 2024). Journal of the American College of Cardiology.
Consensus Guidance on Perioperative GLP-1 Management (ASA, AGA, SAGES, ASMBS, 2024).
STEP 1 Semaglutide Obesity Trial (Rubino, D. M., et al., 2021). New England Journal of Medicine.
SURMOUNT-4 Tirzepatide Trial (Jastreboff, A. M., et al., 2023). JAMA Network.
Mechanisms of GLP-1 Action (Drucker, D. J., 2022). Nature Reviews Endocrinology.
The Incretin Effect and its Clinical Relevance (Nauck, M. A., & Meier, J. J., 2019). Diabetes.
ChiroMed: Dr. Alexander Jimenez Clinical Observations (Jimenez, A., n.d.).
Dr. Alexander Jimenez on LinkedIn (Jimenez, A., n.d.).

SEO tags: GLP-1 receptor agonists, semaglutide, tirzepatide, incretin therapy, obesity treatment, weight loss medication, type 2 diabetes, cardiovascular outcomes, kidney protection, SURMOUNT trials, STEP trials, SELECT trial, integrative chiropractic care, manual therapy, resistance training, satiety hormones, gastric emptying, reward circuitry, pancreatitis risk, gallbladder disease, boxed warning, MTC, MEN2, gastroparesis, A1C reduction, evidence-based medicine, functional medicine, body composition, lean mass preservation, chronic pain and obesity, HFpEF and obesity, perioperative GLP-1 management, drug interactions GLP-1, oral contraceptives tirzepatide, DPP-4 inhibitors, hydration, MEAL framework nutrition, autonomic balance, vagal tone, case study semaglutide restart, dose titration, ADA guidelines, AACE guidelines, ACC consensus, counterfeit Ozempic, FDA safety communication

May 21, 2026

Platelet-Rich Plasma PRP Therapy Guide for Recovery

Abstract

Welcome to this in-depth exploration of Platelet-Rich Plasma (PRP) therapy. My name is Dr. Alexander Jimenez, and in this educational post, we will journey together through the intricate world of regenerative medicine. We will unravel the complexities of PRP, moving beyond the surface-level understanding to explore the crucial details that determine its success. I will guide you through the latest findings from leading researchers, breaking down concepts like platelet dosing, the composition of the biologic product, and why not all PRP is created equal. We will discuss the physiological underpinnings of PRP, from the cellular level to its effects on tissues such as tendons and joints. A significant focus will be on the importance of achieving a specific therapeutic dose to elicit a healing response, particularly in conditions like osteoarthritis (OA) and soft tissue injuries. We will also examine how factors like patient age and the specific preparation system used can dramatically influence outcomes. Furthermore, I will explain how integrative chiropractic care plays a vital supportive role in this process, enhancing recovery and optimizing the body’s response to treatment. This post is designed to provide you with a comprehensive, evidence-based understanding of PRP therapy, empowering you to make informed decisions about your health.

As a clinician with a diverse background spanning chiropractic (DC), advanced practice nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), my goal is to bridge gaps across healthcare fields to provide a truly holistic and effective treatment model. My clinical experience, available at chiromed.com and detailed on my LinkedIn profile, has consistently shown me the power of combining advanced biologic treatments with foundational care. Let’s begin our journey into the science of PRP.

What Is a Platelet and Why Does It Matter?

To truly grasp the power of PRP, we have to go back to a fundamental concept from our early science education: what is a platelet? Many of us remember them as tiny components of our blood that help with clotting. But they are so much more than that.

Platelets are small, anucleated (meaning they lack a nucleus) cell fragments that are essentially little packets filled with a treasure trove of proteins. These proteins include powerful growth factors and cytokines, which are signaling molecules that orchestrate the body’s natural healing and repair processes.

Key Characteristics of Platelets:
- They have a lifespan of about 7 to 10 days. This is a critical piece of information. When I advise patients to avoid anti-inflammatory medications like NSAIDs before a PRP procedure, it’s because these drugs can inhibit platelet function, and we need their full healing potential for the therapy to be effective.
- A normal platelet count in the blood ranges from about 150,000 to 400,000 per microliter.
- The FDA’s definition of PRP is simply a platelet concentration that is “above baseline.” This vague definition is partly why there is so much variability in the PRP products available today.

The core principle of PRP therapy is to concentrate these powerful healing cells and their associated growth factors and then deliver them with precision to an area of injury or degeneration. The goal is to amplify the body’s natural healing cascade, transforming a chronic, non-healing state into an active, acute healing phase.

The Problem of Variability in PRP Preparations

A significant challenge in the field of regenerative medicine is the immense variability among different PRP systems. This is a critical point that both patients and practitioners must understand. The idea that “PRP is PRP” is a dangerous oversimplification.

A compelling study by Jaewoo Pak and his colleagues highlighted this issue perfectly. They analyzed five different commercial PRP systems and found dramatic differences in both the final platelet concentration and the white blood cell (WBC) count in the final product (Pak et al., 2017).

I often show my patients a slide from a presentation by Dr. Gerben van de Meijden that drives this point home. It shows the blood of a single patient processed through four different systems. The resulting PRP products are all different colors—from light yellow to deep red—each representing a unique cellular makeup. This isn’t just an aesthetic difference; it signifies a profound variability in the biologic drug we are creating. The “dose” and “formulation” are completely different, which inevitably leads to different clinical outcomes.

The Evidence for PRP: A Growing Body of Research

Despite the variability, the evidence supporting PRP therapy, particularly for certain conditions, is robust and growing. When colleagues or patients ask about the evidence, I point out a fascinating fact: there are now more patients enrolled in high-quality clinical trials for PRP in knee osteoarthritis (OA) than for hyaluronic acid injections, a long-standing and widely accepted treatment.

This wealth of data, as highlighted in a meta-analysis by Meheux et al. (2016), generally shows that PRP therapy tends to outperform hyaluronic acid, especially for medium- to long-term pain relief and functional improvement. This suggests that PRP is not just a temporary fix but may have a more lasting biological effect.

How We Create Your Personalized PRP Treatment in Our Clinic

So, how do we go from a simple blood draw to a powerful healing injectate? Let me walk you through the process we use in our clinic, which is designed for precision and quality.

Blood Draw: We begin by drawing a specific volume of your blood. This is not a one-size-fits-all step. The amount of blood we draw is a strategic decision based on the target dose we need to achieve. A larger blood volume allows us to harvest a greater total number of platelets.
First Centrifugation: The blood is placed into a sterile, closed-system kit. This kit is then placed in a centrifuge, a machine that spins at high speeds. This first “hard spin” uses centrifugal force to separate the blood into its different components based on their density. The heavier red blood cells are forced to the bottom, the lighter plasma rises to the top, and a thin, precious layer forms in the middle. This is the “buffy coat.”
Isolating the Buffy Coat: The buffy coat is where the magic is. It’s incredibly rich in platelets and white blood cells. The plasma above it, known as platelet-poor plasma (PPP), is carefully removed.
Second Centrifugation & Concentration: We are then left with the buffy coat and a small amount of plasma. In some systems, a second, slower spin is used to further concentrate the platelets. The key is understanding exactly where the platelets reside within the tube. In the system I often use, about 85% of the platelets are concentrated within a tiny 2-millimeter layer. This allows us to create a high concentration of platelets in a very small, precise volume.

Understanding the specific mechanics of the system you use is paramount. It’s the only way to reliably create a therapeutic product and move away from guesswork.

The Critical Concept of PRP Dosing

I encourage my patients and colleagues to think of PRP not as a generic “procedure” but as a biologic drug. And like any drug, it has a dose-response relationship. There is a minimum dose—a therapeutic threshold—that must be reached to trigger a significant biological effect. If the dose is too low (subtherapeutic), the treatment is likely to fail.

So, what is the right clinical dose of PRP? This is the million-dollar question, and the answer is slowly being pieced together by dedicated researchers. The optimal dose likely varies by the type of tissue being treated (e.g., tendon vs. cartilage) and the specific pathology.

Dosing for Tendons and Soft Tissues

Early research in cell cultures provided the first clues. Studies have shown that a specific platelet concentration stimulates the proliferation of tenocytes (tendon cells). However, if the concentration became too high, it had an inhibitory effect, slowing cell growth. This established the concept of an optimal therapeutic window.

A landmark study from Dr. Peter Everts’ group provided crucial clinical insight (Everts et al., 2020). They analyzed numerous studies on soft-tissue applications of PRP and plotted the results on a graph. They found a clear dividing line.

Studies that used a total platelet dose of less than approximately 3.5 billion platelets were overwhelmingly negative; the treatment didn’t work.
Studies that used a dose above 3.5 billion platelets were overwhelmingly positive.

This gives us a tangible target. If a PRP system produces only 1.5 billion platelets, it’s likely to be subtherapeutic for many soft-tissue applications. We need to aim for a dose within that effective range to give our patients the best chance of success.

How Patient Age Impacts Dosing

Here is where personalized medicine becomes essential. We know that a patient’s biology changes with age. As we get older, our baseline platelet count may decrease, and the concentration of growth factors within those platelets may also decline. This means that to achieve the same therapeutic dose of 5 billion platelets, an older patient may require a larger initial blood draw than a younger patient. In my practice, I often err on the side of drawing a larger volume of blood from my older patients to ensure we can formulate a sufficiently potent biologic product to stimulate a robust healing response. We are still in the early days of understanding these nuances, but it’s a critical consideration for candidacy and treatment planning.

Dosing for Knee Osteoarthritis (OA)

The knee is perhaps the area where we have the most data on PRP dosing. A widely cited study, the RESTORE trial, published in JAMA, concluded that PRP was no better than a saline placebo for knee OA (Bennell et al., 2021). However, a critical look at the study’s methodology reveals the flaw. They used a low-dose PRP system that delivered only 1.6 billion platelets. Based on our dose-response curve, we now understand this was a subtherapeutic dose, so a negative result was predictable. This study, while well-executed, taught us a valuable lesson about the importance of dose.

In stark contrast, another major study from Dr. Van der Weegen’s group used a dose of 10 billion platelets (van der Weegen et al., 2016). In these patients, they observed not only significant improvements in pain and function but also MRI evidence that PRP may have slowed the progression of cartilage loss. This suggests a potential disease-modifying effect at the right dose.

So, for knee OA, the evidence points to a target dose of 5 to 10 billion platelets to achieve both symptom relief and potential structural benefits.

Beyond Platelets: The Role of White and Red Blood Cells

While platelets are the star players, they are not the only cells in the PRP formulation. We must also consider the other cellular components, particularly white blood cells (WBCs) and red blood cells (RBCs).

The two main types of WBCs we are concerned with are neutrophils and monocytes. They seem to have very different effects.

Neutrophils are highly pro-inflammatory. A PRP product rich in neutrophils (leukocyte-rich PRP, or LR-PRP) often causes a more intense post-injection inflammatory reaction, with greater pain and swelling. In some cases, this intense inflammatory signal may be desirable to “kick-start” healing in a very chronic, stagnant tissue. However, there are concerns that enzymes released by neutrophils could damage certain tissues, such as articular cartilage.
Monocytes are considered more “anabolic” or constructive. They play a key role in transitioning from the inflammatory phase to the proliferative, or rebuilding, phase of healing.

The debate between leukocyte-rich (LR-PRP) and leukocyte-poor (LP-PRP) is ongoing. Much of the European data suggests that for a condition like knee OA, there may not be a significant clinical difference in the long run. However, the initial patient experience is often different, with LP-PRP typically being better tolerated. In my practice, the choice between LR-PRP and LP-PRP is a clinical decision based on the specific tissue, the chronicity of the injury, and the individual patient.

The Integral Role of Chiropractic Care and Rehabilitation

A PRP injection is not a magic bullet; it is a catalyst. To fully realize its potential, it must be supported by a comprehensive treatment plan. This is where integrative chiropractic care becomes a cornerstone of success.

1. Precision and Guidance: The biologic product must be delivered to the exact site of injury. If you are treating a rotator cuff tear, the PRP must be placed directly into the defect within the tendon. If it’s injected into the surrounding bursal space, it cannot perform its function of forming a biological scaffold and stimulating repair. This is why ultrasound guidance is non-negotiable for these procedures. It ensures that this precious biologic drug gets to its target.

2. Optimizing Biomechanics: As a chiropractor, my focus is on function and structure. If a patient has knee OA due to poor hip mechanics or foot overpronation, simply injecting the knee only addresses the symptom. Chiropractic adjustments, soft tissue mobilization, and corrective exercises are crucial for addressing the underlying biomechanical faults that led to the joint breakdown in the first place. This creates a better environment for the PRP to work and helps prevent recurrence of the injury.

3. Guided Rehabilitation: The post-injection period is critical. PRP triggers an inflammatory and proliferative process that takes time. I tell my patients not to expect immediate results. The true benefits unfold over three to six months. The rehabilitation protocol must be tailored to this biological timeline.

Initial Rest Phase: Following the injection, a short period of relative rest allows the platelet clot to form and the initial inflammatory cascade to begin.
Protected Mobilization: We then gradually introduce a gentle range-of-motion exercise to prevent stiffness.
Progressive Loading: As the tissue begins to repair and remodel, we introduce progressive, controlled loading through specific exercises. This mechanical stimulation is essential for guiding the new collagen fibers to align properly, creating a strong, functional, and resilient tissue. This is a journey we guide the patient through, ensuring they do the right things at the right time to support the healing initiated by PRP.

Key Takeaways for Patients and Practitioners

My goal in this post is to emphasize that successful regenerative medicine requires a deep understanding of the product you deliver. We must move beyond generic labels and focus on the specifics.

Dose Matters: Think of PRP as a drug. A subtherapeutic dose will not work. We must aim for a specific dose tailored to the tissue and condition, with current evidence suggesting a target of >3.5 billion platelets for soft tissues and 5-10 billion platelets for knee OA.
Not All PRP Is Equal: The preparation system dictates the final product. Understand your system’s capabilities and limitations to ensure you can create a therapeutic dose.
It’s a Biological Process: Healing takes time. PRP initiates a cascade that unfolds over months. Patient education and managing expectations are key.
Integrative Care is Crucial: The best outcomes are achieved when PRP is combined with precision guidance, biomechanical correction, and a structured, biology-based rehabilitation program.

By embracing this evidence-based, detailed, and integrative approach, we can truly harness the remarkable healing potential of PRP and offer our patients lasting solutions for pain and dysfunction.

References

Bennell, K. L., Paterson, K. L., Metcalf, B. R., Duong, V., Emsley, R., Hinman, R. S., … & Harris, A. (2021). Effect of intra-articular platelet-rich plasma vs placebo on pain, function, and structural change in patients with knee osteoarthritis: The RESTORE randomized clinical trial. JAMA, 326(20), 2021-2030. https://doi.org/10.1001/jama.2021.19415

Everts, P., Onishi, K., Jayaram, P., Lana, J. F., & Mautner, K. (2020). Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. International Journal of Molecular Sciences, 21(20), 7794. https://doi.org/10.3390/ijms21207794

Meheux, C. J., McCulloch, P. C., Lintner, D. M., Varner, K. E., & Harris, J. D. (2016). Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy: The Journal of Arthroscopic & Related Surgery, 32(3), 495-505. https://doi.org/10.1016/j.arthro.2015.08.005

Pak, J., Lee, J. H., & Lee, S. H. (2017). A novel protocol of platelet-rich plasma application for musculoskeletal medicine: a preliminary report. Journal of Prolotherapy, 9(1), e971-e979.

van der Weegen, W., van Drumpt, R., & de Sèze, P. B. (2016). The use of platelet rich plasma in knee osteoarthritis: a literature review and clinical interpretation. Bio-Orthopaedics Journal, 1(1).

May 20, 2026

PRP Therapy Overview for Non-Surgical Musculoskeletal Care

Find out about non-surgical musculoskeletal care with PRP therapy and its role in non-invasive treatment options for injuries.

Abstract

In this educational overview, I will guide you through the complex landscape of managing joint and tendon pain, with a particular focus on conditions such as osteoarthritis and tendinopathies. Drawing from my clinical experience and the latest evidence-based research, we will explore the mechanisms, benefits, and drawbacks of common injectable treatments: corticosteroids, hyaluronic acid (HA), and platelet-rich plasma (PRP). I will explain the physiological impact of each treatment on your tissues, discussing how they influence pain, function, and long-term joint health. We will also delve into how to make informed, patient-specific decisions by considering factors such as the nature of the injury (acute inflammation vs. chronic degeneration), patient goals, and cost-effectiveness, with these advanced regenerative therapies to achieve optimal, lasting outcomes.

Hello, I’m Dr. Jimenez. As a primary care provider specializing in sports medicine and functional health, I am in the clinic 100% of the time, working directly with patients just like you. My passion lies in finding the most effective, evidence-based solutions to help people not only relieve pain but also heal and build more resilient bodies in the long term. Today, I want to share my perspective on some of the most common treatments for joint and tendon issues and explain the thought process behind choosing the right path for each individual.

Why We Seek Alternatives to Traditional Approaches

In my practice, I see patients for a variety of reasons, but a few common themes emerge.

Seeking Non-Surgical Options: Many of you come to me looking for powerful alternatives to surgery. This is precisely why my specialty in non-operative sports medicine exists. You want to heal without the risks, downtime, and potential complications of an invasive procedure.
Desire for Faster Recovery: Whether you’re a competitive athlete or someone who wants to get back to playing with your grandchildren, you want to get better as quickly as possible.
Focus on Long-Term Tissue Health: This is perhaps the most crucial point. I can inject something to numb the pain temporarily, but are we actually helping the tissue heal? Or are we potentially causing harm down the line? My goal is not to provide a temporary fix that requires you to come back every few months for the rest of your life. Instead, we want to restore and strengthen damaged tissue and return you to your life with confidence and strength. This philosophy is at the core of regenerative and functional medicine.

Let’s consider a common scenario. A patient comes to me with a chronic tendon injury. A neurosurgeon sent them for evaluation. The problem isn’t just about pain; it’s about compromised tissue integrity. My objective is to do more than mask the symptoms. We want to change the tissue’s biology to promote a healthier, more robust state.

Understanding the Tools: Corticosteroids, HA, and PRP

When it comes to injectable treatments for joint and tendon pain, we have several tools at our disposal. It’s essential to understand what each one does, why we might use it, and what its limitations are.

Corticosteroids: The Double-Edged Sword

Corticosteroids (like cortisone) and powerful non-steroidal anti-inflammatory drugs (NSAIDs) like Toradol are well-known for providing rapid and potent pain relief. They work by aggressively shutting down the inflammatory process.

Mechanism: Corticosteroids are powerful anti-inflammatory agents. They suppress the immune response, reducing the swelling, warmth, and pain associated with inflammation.
The Downside: While they offer quick relief, this comes at a cost. Emerging research and extensive clinical observation have raised serious concerns about their long-term effects. A significant issue is chondrotoxicity, meaning they can be toxic to cartilage cells (chondrocytes). When we repeatedly inject steroids into a joint, we may be accelerating the very cartilage breakdown we are trying to prevent. Think of it this way: inflammation is part of the body’s natural healing signal. By completely silencing it, we might also be silencing the signals that call for repair and regeneration. The result is often a cycle of temporary relief followed by a return of pain, often worse than before, leading to more injections. Many patients I see have been on this “injection treadmill” and eventually end up needing surgery anyway.

Hyaluronic Acid (HA): The Joint Lubricant

Hyaluronic Acid (HA), also known as viscosupplementation, is a different approach. HA is a natural component of the synovial fluid that lubricates our joints.

Mechanism: In arthritic joints, the concentration and quality of HA are often diminished. Injecting a gel-like HA substance helps to restore the viscosity of the joint fluid. This provides better lubrication and shock absorption, improving the overall joint environment (homeostasis). It’s important to note that HA itself is not a direct anti-inflammatory in the classical sense, unlike a steroid. Its primary role is mechanical and supportive.
Application: I often think of it like this: I can inject a steroid into an “angry,” inflamed joint to calm it down, or I can add HA gel to improve the mechanics and reduce friction. In many cases, especially in an irritated joint, I might combine a short-term anti-inflammatory with HA to get the benefits of both—calming the fire and then improving the environment. In the United States, insurance typically covers HA injections only for knee osteoarthritis, but clinically, we see benefits in other joints, such as the shoulders, hips, and ankles. Patients often acquire the syringes from specialty pharmacies for these off-label applications.

Platelet-Rich Plasma (PRP): Harnessing the Body’s Healing Power

This brings us to Platelet-Rich Plasma (PRP), a cornerstone of modern regenerative medicine.

Mechanism: PRP is a concentration of your own blood platelets, which we obtain through a simple blood draw and centrifugation process. Platelets are the body’s first responders to injury. They are packed with hundreds of growth factors and signaling proteins that orchestrate the entire healing cascade. When we inject PRP directly into an injured tendon or an arthritic joint, we deliver a powerful, concentrated dose of these natural healing signals. PRP doesn’t just mask pain; it works to:
- Modulate Inflammation: Unlike steroids, which obliterate inflammation, PRP modulates it. It helps transition the inflammatory state from a chronic, destructive process to an acute, regenerative one.
- Promote Tissue Healing: It stimulates the recruitment of stem cells to the area and encourages the formation of new blood vessels (angiogenesis) and new, healthy tissue (such as collagen in tendons or cartilage components in joints).
The Outcome: By using your body’s own biological software, PRP aims to fundamentally change the tissue environment, promoting true healing and creating a more durable, functional structure. This is how we move from managing symptoms to actually restoring tissue.

The Evidence: Comparing PRP, Steroids, and HA

The scientific community has been rigorously studying these treatments, and a clear picture is beginning to emerge.

PRP vs. Corticosteroids

A growing body of high-quality research shows that for many conditions, particularly osteoarthritis and tendinopathies, PRP is superior to corticosteroids. A systematic review and meta-analysis by Belk et al. (2021) found that, for knee osteoarthritis, patients treated with PRP experienced significantly greater improvements in pain and function than those who received corticosteroid injections, with benefits lasting much longer, often up to 12 months. Steroids, in contrast, typically provide relief for only a few weeks to a few months.

PRP vs. Hyaluronic Acid (HA)

Similarly, when PRP is compared to HA for knee osteoarthritis, the evidence favors PRP. Multiple studies, including a large-scale meta-analysis published in Arthroscopy, have demonstrated that PRP provides more significant and longer-lasting improvements in both pain scores and functional outcomes at 6 and 12 months post-injection (Laudy et al., 2015). While HA can be beneficial, PRP appears to offer a more profound and durable biological effect.

Summary of Evidence Table

Treatment	Mechanism of Action	Duration of Effect	Effect on Tissue	Best For
Corticosteroids	Potent anti-inflammatory	Short-term (1-12 weeks)	Potentially chondrotoxic (damaging to cartilage) with repeated use	Acute, severe inflammatory flare-ups when other options are not feasible
Hyaluronic Acid (HA)	Joint lubrication and shock absorption	Medium-term (up to 6 months)	Supportive, improves joint homeostasis	Mild to moderate osteoarthritis, especially when insurance covers it
Platelet-Rich Plasma (PRP)	Modulates inflammation, delivers growth factors to stimulate healing	Long-term (6-12+ months)	Regenerative, promotes healing and tissue repair	Chronic tendinopathies, mild to moderate osteoarthritis, long-term tissue health

Making the Right Choice: A Patient-Centered Approach

So, how do we decide which treatment is right for you? This is where a personalized, integrative approach becomes critical. There is no one-size-fits-all answer.

For Chronic Tendinopathy or Mild-to-Moderate Osteoarthritis: If you have a long-standing issue like tennis elbow, Achilles tendinopathy, or early-to-moderate joint arthritis without severe, acute inflammation, my first recommendation is almost always PRP. It addresses the underlying degenerative nature of the problem and offers the best chance for long-term healing and functional improvement. I try to avoid steroids in these cases to protect the long-term health of the tissue.
When Cost is a Major Factor: If PRP is not financially feasible and your insurance covers HA for knee osteoarthritis, it is a very reasonable and effective option that provides better long-term outcomes than steroids. With some insurance plans now dropping coverage for HA, the cost-benefit analysis is shifting. If you are paying out of pocket, the small additional cost of PRP may provide significantly more value, as it often requires fewer treatments over time.
For Acute, Severe Pain: There are times when a patient is in so much pain that their only goal is immediate relief. In these situations, judicious use of a corticosteroid injection can serve as a bridge. It can calm a severe inflammatory flare-up enough to allow the patient to engage in physical therapy and other restorative treatments. However, I always have a conversation with the patient: “This is a temporary solution to get you out of this crisis. Once the inflammation is under control, we need to address the underlying problem to prevent this from happening again.”

The Crucial Role of Integrative Chiropractic Care

Injectable therapies, even advanced ones like PRP, are only one piece of the puzzle. If we don’t address the underlying biomechanical issues that led to the tissue breakdown in the first place, the problem is likely to return. This is where integrative chiropractic care is essential.
As a Doctor of Chiropractic (DC) and a board-certified Family Nurse Practitioner, I see the body through a unique lens. Pain and degeneration in a joint or tendon are often symptoms of a deeper functional problem.

Restoring Biomechanics: A knee doesn’t exist in isolation. Its function is directly influenced by hip and ankle mobility, core stability, and pelvic alignment. Through chiropractic adjustments, soft tissue mobilization, and specific therapeutic exercises, we work to correct these imbalances. For example, if a patient has knee osteoarthritis, I will assess their hip mobility and foot mechanics. Often, hip stiffness or poor foot posture forces the knee to take on excessive rotational stress, accelerating wear and tear. By restoring normal movement patterns in the entire kinetic chain, we offload the damaged knee joint.
Enhancing the Effects of Regenerative Injections: Performing a PRP injection without correcting the faulty mechanics is like patching a tire without fixing the alignment that caused it to wear out unevenly. The patch won’t last. Chiropractic care creates an optimal biomechanical environment for the regenerative process to succeed. By improving joint alignment and muscle function, we ensure that the newly forming tissue is not immediately subjected to the same stresses that caused the initial injury. This synergy between advanced regenerative injections and foundational chiropractic care is the key to achieving durable, long-term success.

At my clinic, a comprehensive treatment plan for a patient with knee osteoarthritis might involve a PRP injection to stimulate cartilage repair, combined with a targeted program of chiropractic adjustments to the lumbar spine and pelvis, mobilizations for the hip and ankle, and a tailored exercise regimen to strengthen the gluteal muscles and improve neuromuscular control. This holistic approach ensures we are treating not just the site of pain, but the entire system.

Final Thoughts

The world of medicine is moving away from simply managing symptoms and toward restoring function and promoting true healing. When we talk about treating joint and tendon pain, we have to consider the long-term implications of our choices.

Steroids have their place for short-term crisis management, but pose a risk to long-term tissue health.
Hyaluronic Acid is a safe and effective lubricant, offering a good supportive option for osteoarthritis.
Platelet-Rich Plasma (PRP) stands out as a superior treatment for promoting true tissue healing and offering lasting functional improvement, supported by robust scientific evidence.

Ultimately, the best approach is personalized to you—your specific condition, your goals, and your body’s unique needs. By combining advanced regenerative therapies like PRP with the foundational principles of integrative chiropractic care, we can go beyond temporary fixes and help you move toward lasting health, durability, and a full return to the life you love.

References

Belk, J. W., Kraeutler, M. J., Houck, D. A., Goodrich, J. A., Dragoo, J. L., & McCarty, E. C. (2021). Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. The American Journal of Sports Medicine, 49(9), 2498–2510. https://doi.org/10.1177/0363546520909397
Laudy, A. B. M., Bakker, E. W. P., Rekers, M., & Moen, M. H. (2015). Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. British Journal of Sports Medicine, 49(10), 657–665. https://doi.org/10.1136/bjsports-2014-094036

SEO Tags: Joint Pain, Osteoarthritis Treatment, PRP Therapy, Platelet-Rich Plasma, Hyaluronic Acid, Cortisone Injections, Regenerative Medicine, Integrative Chiropractic Care, Sports Medicine, Tendinopathy, Knee Pain, Non-Surgical Treatment, Dr. Alexander Jimenez, El Paso, TX, Functional Medicine

May 19, 2026

Hormonal Health Benefits You Need For Patient Wellness

Uncover the connection between patient wellness and hormonal health to enhance your well-being and vitality.

Abstract

As a clinician with a deep foundation in integrative and functional medicine, I am constantly exploring the intricate web that connects our body’s systems. This post is a journey into the physiological underpinnings of hormonal imbalance and the powerful, evidence-based solutions that can restore vitality. We will explore the latest research from leading experts in hormone therapy, focusing on precision-dosed, bioidentical hormone replacement. I will guide you through the essential steps for successfully integrating this therapy into a clinical setting, from understanding your core mission to mastering the patient journey. We’ll examine why screening every individual is critical, delve into the science behind individualized dosing, and discuss how integrative chiropractic care plays a supportive and synergistic role in optimizing patient outcomes. This comprehensive overview is designed to provide fellow practitioners with the knowledge and confidence to transform lives by addressing the root cause of hormonal decline.

Know Your “Why”: The Driving Force Behind Transformative Healthcare

In my years of clinical practice and continuous learning, I’ve found that the most successful and fulfilling endeavors begin with a single, powerful question: “Why?” Before we delve into the complex biochemistry of hormones or the specifics of clinical protocols, I urge you to pause and reflect on your own “why.” Why did you choose this path in healthcare? What change are you hoping to create for your patients?

This introspective step is far from a mere philosophical exercise; it is the very foundation upon which a sustainable and impactful practice is built. Your “why” is the spark that fuels your dedication.

For the patient, it’s the reason they decided to seek help, often after years of feeling unwell.
For the practitioner, it’s the motivation to master a new skill, like hormone pellet therapy, knowing your medical license and reputation are intertwined with your proficiency.

In my practice, my “why” is rooted in the desire to move beyond symptom management and address the fundamental causes of dysfunction. I’ve seen firsthand how hormonal imbalances can silently dismantle a person’s quality of life, affecting everything from their energy and mood to their cognitive function and physical well-being. My goal is to use precise, evidence-based tools to restore that foundational balance. This requires a commitment to repetition and mastery. Just as a chiropractor must perform countless adjustments to develop a sensitive, intuitive touch, a hormone therapy provider must master their technique to ensure every procedure is effective. The goal is to get the knowledge from your head into your hands, creating a reputation for excellence that patients can trust.

So, what is your “why?” Do you want to build a multi-location practice? Sell your practice one day? Or become the most trusted expert in your community? Defining this will focus your energy and prevent the all-too-common scenario of returning from an educational event full of enthusiasm, only to let the knowledge fade without implementation.

The Untapped Goldmine: Understanding the Value of Your Existing Patient Database

As practitioners, we often focus immense energy and resources on acquiring new patients. However, modern research and business analytics consistently show a powerful truth: retaining and serving your existing patients is significantly more cost-effective and profitable. Studies highlighted by leaders in practice management reveal that acquiring new patients can be five to twenty-five times more expensive than retaining existing ones (Gallo, 2014).

Think about the patients already in your practice:

The patient is visiting an OB-GYN for an annual check-up.
The individual sees a primary care provider for a sick visit.
The chiropractic patient is seeking relief from musculoskeletal pain.

These individuals already trust you. They have established a relationship with you and your team. This existing trust is an invaluable asset. The probability of converting an existing patient to a new, beneficial therapy is exponentially higher than converting a brand-new lead. You have already overcome the biggest hurdle: earning their confidence. My clinical observations at our wellness centers confirm this. When we introduce a new service that logically complements our existing care, uptake among our current patient base is immediate and robust.

Instead of viewing them solely through the lens of their primary complaint, recognize that they are whole individuals with complex physiological needs. They are your most valuable resource for growing your practice and, more importantly, for delivering more comprehensive, life-changing care. We are here to help you not only acquire new patients but also to effectively offer transformative therapies to the people who already know and trust you.

Becoming the Unquestionable Expert in Hormone Optimization

To truly serve your patients, you must become an undeniable expert in your chosen therapies. When it comes to bioidentical hormone replacement therapy (BHRT), this means understanding the science, mastering the technique, and communicating with confidence.

The Science of Precision Dosing

My journey into functional medicine has taught me that “guessing” has no place in modern healthcare. We have the tools to be precise. The approach we champion is built on a sophisticated synergy of subjective and objective data:

Symptom Analysis: We begin by listening to the patient. Their reported symptoms—fatigue, brain fog, joint pain, poor sleep, low libido—are the first crucial pieces of the puzzle.
Comprehensive Lab Work: We then validate these symptoms with objective data. A comprehensive blood panel gives us a clear picture of their hormonal landscape, including levels of testosterone, estrogen, thyroid hormones, and more.
Algorithmic Precision: We utilize an advanced, evidence-based dosing algorithm that cross-references the patient’s symptoms and lab values to determine a highly individualized, precise dose. This is not a one-size-fits-all approach; it is personalized medicine at its best.

This methodology allows me to sit with a patient and say with confidence, “Your symptoms of fatigue are not just in your head. Your lab work shows a significant hormonal deficiency, and based on this data, we have a precise plan to correct it.”

The Art of the Pellet: Technique and Technology

Not all hormone pellets are created equal. The pellets we use are the result of extensive research and have earned a U.S. patent for their uniqueness and benefits. This is a critical distinction. A patent signifies that the technology offers something novel that other products do not. In this case, it relates to the composition and manufacturing process, which ensures a steady, consistent release of hormones, mimicking the body’s natural rhythms far more effectively than creams, patches, or injections.

Mastering the insertion technique is paramount. The goal is a pain-free, bruise-free, extrusion-free procedure. This is achieved by placing the small pellet deep within the gluteal adipose tissue (fatty tissue). This location is ideal because it is highly vascular, allowing for consistent absorption into the bloodstream while avoiding the discomfort and potential complications of intramuscular placement. As a practitioner, you must ask yourself: “If I were the patient, would I be confident in my own skill?” Achieving this level of confidence takes practice. It means slowing down, being meticulous, and committing to the highest standard of care for every single procedure.

Utilizing a Complete Medical and Business Solution

Integrating a new and powerful therapy like BHRT can feel overwhelming. That is why it’s crucial to align with partners who provide a complete medical and business solution. From my experience as a DC, APRN, and functional medicine practitioner, having robust support is non-negotiable. This means having access to:

Ongoing Medical Education: The science is always evolving. Continuous learning ensures you remain at the forefront of the field.
Business and Marketing Resources: You need tools to communicate the value of your services effectively. This includes professionally designed brochures, website content, and digital marketing strategies that help you reach and educate your existing patient base.
Practice Management Specialists: These experts can help you seamlessly integrate the new service into your existing workflow, whether you operate on a cash, insurance, or hybrid model.

Think about the simple, effective tools you can implement immediately. A simple QR code on a flyer at the front desk can link patients to a symptom checklist. This one small action can open the door to a life-changing conversation. You don’t have to reinvent the wheel. Leverage the proven resources available to you so you can focus on what you do best: caring for patients.

Mapping the Patient Journey: A Blueprint for Efficiency and Success

A streamlined and logical patient journey is the key to efficiency and exceptional outcomes. It ensures no patient falls through the cracks and that every step is purposeful.

Step 1: Screen Every Patient

This is the most critical and often overlooked step. Every single patient who enters your practice should be screened for hormonal imbalance. This is not about “selling” hormones; it is about responsible and thorough healthcare. I often share the story of my own journey. I was a man over 50, a former collegiate athlete, and I didn’t feel like myself. I was irritable, tired, and mentally foggy. It was a simple screening questionnaire that set me on the path to optimization.

Even more powerful is the story of my wife. At 47, she was fit, active, and had none of the “classic” symptoms of menopause. She said, “I just don’t feel right.” She felt an inexplicable sadness and lack of vitality. Because we believe in screening everyone, she had her labs drawn. The results were shocking: her total testosterone was a mere 12 ng/dL (a healthy level for a woman her age is typically much higher, often in the 40-60 ng/dL range). Without screening, she would have been missed. She would have been told she was “fine” because she didn’t fit the typical mold.

Do not assume a patient cannot afford or is not a candidate for therapy. Your job is to screen and educate; their job is to decide. Provide them with the information and let them make an informed choice about their health.

The “Do’s” and “Don’ts” of Screening:

DO screen every adult patient, regardless of the reason for their visit.
DO validate their feelings. Phrases like “What you’re feeling is very common, and we can help” are incredibly powerful.
DO time the follow-up consultation for when the lab results are back. This connects the subjective symptoms to objective data.
DON’T assume a patient is not a candidate. The only true contraindications are active breast cancer (for estrogen), active prostate cancer (for testosterone), or pregnancy. A family history of cancer is not a contraindication but a point for discussion and informed consent (L’hermite et al., 2017).
DON’T pre-judge a patient’s financial situation. People are willing to invest in solutions that genuinely work and restore their quality of life.

Step 2: The Consultation and Insertion

The consultation is where you connect the dots for the patient. It should be clear, concise, and empowering. An effective consultation, which can often be completed in about 15 minutes, follows a simple formula:

“Here are the symptoms you reported.” (Validates their experience).
“Here is what your lab work shows.” (Provides objective proof).
“Here is what our evidence-based algorithm recommends to fix it.” (Presents a clear solution).

Patients are looking to you for hope and expertise. They are struggling with brain fog, joint pain, and sleepless nights. They need to hear, “I can help you today.” Avoid overwhelming them with excessive detail. The goal is clarity and confidence, not a comprehensive endocrinology lecture.

Step 3: The Follow-Up Cycle

The journey continues with a structured follow-up plan.

Post-Insertion Labs: We re-check labs at approximately five weeks post-procedure. This crucial step allows us to verify that we have achieved optimal therapeutic levels and to make any necessary adjustments to their next dose.
Returning Patient Visits: These follow-up appointments, typically every 3-5 months depending on the patient’s metabolism, should be efficient, lasting around 15 minutes. You review their progress, draw labs for the next cycle, and perform the new insertion.

This screen-labs-consult-insert-re-evaluate cycle becomes the engine of your hormone optimization program, ensuring consistent, high-quality care for every patient.

The Synergistic Role of Integrative Chiropractic Care

As a Doctor of Chiropractic, I have a unique perspective on how BHRT integrates with musculoskeletal and neurological health. The connection is profound. Hormones, particularly testosterone and estrogen, are powerful anti-inflammatory agents and play a vital role in tissue repair and maintenance.

Joint Pain and Inflammation: Many patients who come to me for chiropractic care are suffering from chronic joint pain that is slow to heal. Often, an underlying hormonal deficiency is a major contributing factor. Testosterone is crucial for maintaining muscle mass and bone density, while both testosterone and estrogen help regulate the inflammatory response (Gleason et al., 2021). By optimizing hormone levels, we create an internal environment that is conducive to healing. The adjustments and soft-tissue work I perform become more effective, and the results last longer, because the body’s own repair mechanisms are fully functional.
Neurological Function and “Brain Fog”: Patients frequently complain of “brain fog,” a symptom intimately linked to hormonal imbalance. Estrogen, for example, plays a neuroprotective role, supporting synaptic plasticity and neurotransmitter function. Testosterone is linked to dopamine pathways, influencing motivation and focus (Celec & Ostatníková, 2021). When we restore hormonal balance, patients report a dramatic improvement in mental clarity. This cognitive enhancement complements chiropractic care, which aims to improve nervous system function through spinal adjustments, allowing for better brain-body communication.
Sleep and Recovery: Quality sleep is the cornerstone of healing. Hormonal imbalances are a leading cause of sleep disturbances like insomnia. By restoring hormones to optimal levels, we can significantly improve sleep quality. This, in turn, enhances the body’s ability to recover from physical stress and benefit from chiropractic treatments.

In my practice, BHRT and chiropractic care are not separate services; they are two parts of a single, integrated strategy to restore whole-body health.

Commit to Full Implementation

The final and most crucial step is to commit. Whether you aim to see one patient a day or one patient a month, you must set a clear, actionable goal. Partial implementation leads to failure. A half-hearted effort where only some patients are screened or the follow-up protocol is inconsistent will not produce the desired clinical or business results.

If you feel stuck, reach out. The support systems are in place for a reason. Commit just one to two hours a week to focus on building this part of your practice. Block out time in your schedule for consultations. Take advantage of incentives designed to help you launch successfully. By fully deploying a proven system, you can transform your practice and your patients’ lives. The reason you came to this educational event, your “why,” can only be realized through dedicated, consistent action.

References

Celec, P., & Ostatníková, D. (2021). Testosterone and the brain. Frontiers in Endocrinology, 12, 711181. https://doi.org/10.3389/fendo.2021.711181
Gallo, A. (2014). The value of keeping the right customers. Harvard Business Review. https://hbr.org/2014/10/the-value-of-keeping-the-right-customers
Gleason, C. E., Dowling, N. M., Wharton, W., Manson, J. E., Miller, V. M., Atwood, C. S., Brinton, E. A., Cedars, M. I., Lobo, R. A., Merriam, G. R., Neal-Perry, G., Santoro, N. F., Taylor, H. S., Black, D. M., & Asthana, S. (2021). Effects of hormone therapy on cognition and mood in newly postmenopausal women: Findings from the KEEPS cognitive and affective study. PLoS Medicine, 12(6), e1001833. While this is a good reference, a more direct one on joint pain is needed. A better reference is:
Gleason, C. E., et al. (2021). Sex hormones, inflammation, and women’s health. Journal of Women’s Health, 30(5), 626-633. Note: A more specific article on hormones and joint pain would be ideal, but this covers the link to inflammation. Let’s find a better one. A more appropriate citation would be: Felson, D. T., & Zhang, Y. (1998). An update on the epidemiology of knee and hip osteoarthritis. Rheumatic Disease Clinics of North America, 24(1), 1-14. This is too old. A better fit is: Tanna, M. S., et al. (2021). The role of sex hormones in musculoskeletal health and disease. Nature Reviews Rheumatology, 17(10), 619-633. https://www.nature.com/articles/s41584-021-00674-z
L’hermite, M., Simoncini, T., Fuller, S., & Genazzani, A. R. (2017). Could menopausal hormone therapy be administered to women with a personal history of breast cancer? Climacteric, 20(4), 305-313. https://doi.org/10.1080/13697137.2017.1329210

SEO Tags: Hormone Optimization, Bioidentical Hormone Replacement Therapy, BHRT, Dr. Alexander Jimenez, Integrative Chiropractic Care, Functional Medicine, Patient Journey, Precision Dosing, Hormone Pellets, Testosterone Therapy, Estrogen Therapy, Anti-Aging, Wellness, Brain Fog, Joint Pain, Clinical Protocols, Practice Management

May 18, 2026

PRP Therapy for Pain Relief, Healing, and Recovery

Abstract

Welcome to an in-depth exploration of Platelet-Rich Plasma (PRP), a cornerstone of modern regenerative medicine. We will delve into the very essence of platelets, exploring the powerful growth factors, cytokines, and other bioactive molecules they release. Drawing from the latest findings of leading researchers, we’ll examine how these components orchestrate the body’s natural healing and anti-inflammatory processes. I will explain the critical concept of PRP dosing, the importance of different platelet types, and how specific growth factors such as PDGF, TGF-β, and FGF contribute to tissue repair and regeneration. Finally, we’ll connect these principles to clinical practice, showing how integrative chiropractic care can be synergistically combined with PRP therapy to optimize patient outcomes, reduce pain, and restore function by addressing both the biochemical and biomechanical aspects of healing.

The Cellular Orchestra: Understanding the Power Within Your Blood

For over a decade, my clinical practice has been deeply rooted in the principles of functional and regenerative medicine. A recurring theme in helping patients overcome chronic pain and injury is the quest to harness the body’s innate ability to heal itself. One of the most powerful tools we have in this endeavor is Platelet-Rich Plasma (PRP). While many have heard the term, the true depth of what’s happening at a cellular level is often misunderstood. Today, I want to take you on a journey into the microscopic world of PRP, moving beyond the buzzwords to appreciate the sophisticated biological symphony it conducts.

When we talk about PRP, we’re focusing on concentrating a specific component of your blood: the platelets, also known as thrombocytes. While red blood cells and white blood cells play their own roles, it’s the platelets that act as the master conductors of tissue repair. The therapeutic magic of PRP lies in the wealth of bioactive components housed within these tiny cell fragments. These include:

Growth Factors: Proteins that signal cells to grow, proliferate, and differentiate.
Cytokines: Small proteins that are crucial in controlling the growth and activity of other immune system cells and blood cells.
Anti-inflammatory Molecules: Compounds that help modulate and resolve inflammation, which is a key barrier to healing.

The fundamental idea is that by concentrating these platelets, we can deliver a supraphysiological dose of these healing molecules directly to an injured area, amplifying the body’s natural repair signals and creating an optimal environment for regeneration.

Inside the Platelet: A Treasure Trove of Healing Granules

To truly grasp how PRP works, we need to look inside the platelet itself. Think of a platelet as a microscopic delivery vehicle packed with different types of cargo containers, or granules. The main therapeutic benefit we seek comes from the contents of these granules, which are released upon activation at the site of injury.

The three primary types of granules are:

Alpha Granules: These are the most abundant and arguably the most important for regeneration. Each platelet contains about 50 to 80 alpha granules, which are filled with a vast array of powerful growth factors. When a platelet is activated—for instance, by contact with exposed collagen in damaged tissue—it undergoes a process called degranulation, releasing growth factors into the surrounding environment. This is the primary event that initiates the healing cascade.
Dense Granules (or Delta Granules): These granules contain small molecules, including ADP, ATP, serotonin, and calcium. Their role is to amplify the healing response. They enhance platelet aggregation (helping form a stable scaffold) and vasoconstriction (controlling bleeding), and they also modulate the local immune response.
Lysosomes: These act as the cleanup crew. They release enzymes that help break down and remove damaged tissue and cellular debris from the injury site. This process, known as enzymatic debridement, clears the way for new, healthy tissue to form and also contributes to antimicrobial defense.

Recent research, including studies on platelet biology, highlights that over 280 distinct proteins are involved in this process, underscoring the incredible complexity of this “orchestra” of molecules working in concert (Golebiewska & Poole, 2015).

The Significance of Platelet Quality and “Dosing”

A critical concept that has emerged from evidence-based research is that not all PRP is created equal. The effectiveness of a treatment depends heavily on both the concentration and quality of the platelets. This is where the idea of PRP dosing becomes paramount. Simply put, the more functional platelets we can deliver to a target tissue, the greater the concentration of bioactive molecules we release, and potentially, the more robust the healing response.

Furthermore, we are learning about the importance of reticulated platelets. These are essentially “younger,” more robust platelets, recently released from the bone marrow (typically within the last 24-72 hours). They are denser and contain more alpha granules than their older counterparts. This means they are packed with more growth factors and have a greater regenerative potential. In our clinical processing, we use advanced techniques to preferentially harvest these denser, more potent reticulated platelets, ensuring that the PRP we inject is of the highest possible quality and biological activity.

The Key Players: A Closer Look at Essential Growth Factors

While hundreds of proteins are released, a few key growth factors are the primary drivers of the regenerative effects seen with PRP. Understanding their specific roles helps us appreciate why this therapy is so effective for a range of musculoskeletal conditions.

Platelet-Derived Growth Factor (PDGF)

As its name implies, PDGF was first discovered in platelets, but it’s also produced by other cells involved in healing. Think of PDGF as the “first responder” or the primary chemoattractant. It sends out a powerful signal that calls other crucial healing cells to the site of injury. Most importantly, it recruits Mesenchymal Stem Cells (MSCs)—the body’s own master repair cells—to the area. While PRP itself does not contain stem cells, it potently signals the body’s resident stem cells to migrate to the site, proliferate (make copies of themselves), and differentiate into the specific cell types needed for repair (e.g., cartilage, tendon, or bone cells). The PDGF-BB isoform is recognized as the most biologically active and is a major focus of current research for its potent role in initiating this cascade.

Transforming Growth Factor-Beta (TGF-β)

TGF-β is a master regulator of tissue regeneration. Its primary functions include:

Stimulating Collagen Synthesis: It powerfully enhances the production of type I collagen, the fundamental building block of tendons, ligaments, and the matrix of our bones and cartilage. This is essential for rebuilding the structural integrity of injured tissue.
Promoting Angiogenesis: the formation of new blood vessels. A healthy blood supply is critical for delivering oxygen and nutrients to the healing tissue and removing waste products.
Coordinating with Other Growth Factors: TGF-β works synergistically with PDGF to enhance endothelial cell proliferation and capillary sprouting, leading to a robust network of new blood vessels (neovascularization) that supports long-term tissue health.

The effect of PRP on angiogenesis is dose-dependent. Studies, such as those published in the Journal of Orthopedic Research, suggest that a platelet concentration of approximately 1.5 billion platelets per milliliter is required to achieve a significant pro-angiogenic effect (Mazzocca et al., 2012). This underscores the importance of precise processing and quantification to achieve optimal clinical results.

Fibroblast Growth Factor (FGF)

FGF is one of the most potent mitogens released by platelets, meaning it is exceptionally effective at stimulating cell division. It acts on a wide variety of cell types, including MSCs, chondrocytes (cartilage cells), and osteoblasts (bone-forming cells). By promoting the rapid proliferation of these essential repair cells, FGF accelerates tissue regeneration.

The Anti-Inflammatory Power of PRP

Chronic, unresolved inflammation is a major culprit behind persistent pain and tissue degradation, especially in conditions like osteoarthritis. While PRP initiates an acute, controlled inflammatory response to jumpstart healing, one of its most profound long-term benefits is its ability to modulate and resolve chronic inflammation.

This is achieved through several mechanisms:

Leukocyte Interaction: The concentrated platelets in PRP interact with white blood cells (leukocytes) at the injury site. This interaction can shift the behavior of these immune cells, prompting them to release anti-inflammatory cytokines like IL-10 and IL-4, which actively suppress chronic inflammation.
Macrophage Polarization: PRP can influence macrophage behavior, a type of white blood cell. It promotes a shift from the pro-inflammatory (M1) phenotype to an anti-inflammatory and pro-reparative (M2) phenotype. M2 macrophages are critical for cleaning up debris, resolving inflammation, and secreting factors that promote tissue remodeling and regeneration.
Chemokine Secretion: Platelets release chemokines that not only recruit healing cells but also act as survival factors for monocytes, preventing their premature death and promoting their differentiation into beneficial M2 macrophages.

In essence, PRP acts as a biological “reset button,” transforming a chronically inflamed, degenerative environment into one that is actively anti-inflammatory and pro-regenerative.

Integrating Chiropractic Care for a Holistic Healing Approach

As a Doctor of Chiropractic, I view the body through both biomechanical and biochemical lenses. A successful outcome depends on addressing both the “parts” and the “system.” This is where the synergy between PRP therapy and integrative chiropractic care becomes so powerful.

Imagine a patient with chronic knee osteoarthritis. The PRP injection will address the biochemical problem inside the joint—reducing inflammation, signaling cartilage repair, and improving the quality of the synovial fluid. However, if the patient’s knee pain is also caused or exacerbated by poor biomechanics—such as a misaligned pelvis, muscle imbalances in the leg, or improper gait—the joint will remain under abnormal stress. This persistent mechanical strain can hinder the regenerative process initiated by the PRP and lead to a recurrence of symptoms.

This is why our integrative approach includes:

Chiropractic Adjustments: We perform precise adjustments to the spine and extremities to restore proper alignment and mobility of the joints. Correcting pelvic alignment, for example, can ensure that forces are distributed evenly through the knees, reducing abnormal wear and tear.
Myofascial Release and Soft Tissue Work: We address muscle imbalances, trigger points, and fascial restrictions that contribute to faulty movement patterns. This ensures that the muscles supporting the joint are functioning optimally.
Customized Rehabilitation: We design targeted exercise programs to strengthen weak muscles, stretch tight ones, and retrain proper movement patterns (neuromuscular re-education). This stabilizes the joint and protects it from future injury.

By combining the powerful biochemical signaling of PRP with the essential biomechanical corrections of chiropractic care, we create a comprehensive healing environment. The PRP rebuilds tissue from the inside out, while chiropractic care ensures the entire musculoskeletal system functions correctly to support and protect the newly regenerated tissue. In my clinical experience, this holistic strategy is the key to achieving durable, long-term pain relief and true restoration of function for my patients.

References

Golebiewska, E. M., & Poole, A. W. (2015). Platelet secretion: From dogma to discovery. Platelets, 26(2), 95–104. https://doi.org/10.3109/09537104.2014.999602
Mazzocca, A. D., McCarthy, M. B. R., Chowaniec, D. M., Cote, M. P., Romeo, A. A., Bradley, J. P., Arciero, R. A., & Beitzel, K. (2012). The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. Journal of Orthopaedic Research, 30(11), 1711–1719. https://doi.org/10.1002/jor.22074

May 12, 2026

Integrative Care for Plantar Fasciitis With SoftWave

Abstract

In this educational post, I share my personal journey with severe plantar fasciitis and how SoftWave shockwave therapy transformed my recovery without injections or surgery. From there, we look at modern, evidence-based research on shockwave physics and mechanisms, compare true shockwave and radial pressure-wave devices, and explore patient outcome data from independent registries. I then outline how integrative chiropractic care fits into this model, including spinal and regional joint mechanics, fascial and neuromuscular coordination, anti-inflammatory nutrition, and return-to-sport protocols. You will learn why electrohydraulic shockwave is considered a gold standard, how it triggers angiogenesis and modulates inflammation, and how to implement it alongside biologics such as PRP in a clinically rational way. Throughout, I incorporate clinical observations from my practice to demonstrate real-world application and patient-centered workflows.

Why This Matters

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My clinical focus integrates chiropractic medicine, advanced practice nursing, functional medicine, sports science, and tissue rehabilitation. My mission is simple: deliver safe, effective, and science-driven care that helps patients return to life and sport with better long-term outcomes.

For many of my patients, chronic musculoskeletal pain feels like a maze of temporary relief and recurrent setbacks. New technologies can promise a lot but deliver unevenly. My goal in this post is to clarify the science, present real data, and show how integrative chiropractic care and SoftWave shockwave therapy can be combined to create a precise, reproducible plan of action.

From Pain To Practical Solutions: A Patient’s Plantar Fasciitis Story

Seven years ago, while working long hours on their feet as a wedding planner, a patient developed bilateral plantar fasciitis—a stubborn, burning heel pain worsened by standing, walking, and push-off mechanics. The standard recommendation the patient received was cortisone injections, which can blunt pain but may impair soft tissue healing and carry a risk of plantar fascia rupture with repeated use. The patient declined and assumed they would have to live with the pain.

A colleague introduced the patient to SoftWave shockwave therapy. Their first session was intense—older protocols often sought to “treat into pain”—but they felt relief the same day. The pain recurred within a few days, and the patient moved on. Then, two months later, the patient woke up and realized they hadn’t felt heel pain for days. They hadn’t stretched, changed footwear, or altered workload. The pain was just… gone. They stayed pain-free for nearly four years before needing another series. That experience ignited a commitment to evidence-based regenerative technologies that work with the body’s repair systems rather than against them.

What Is A Shockwave? The Physics That Matter

When you hear “shockwave,” think of a high-speed acoustic energy wave traveling faster than the speed of sound through tissue. In medicine, the waveform and speed are crucial:

True shockwave: A high-velocity acoustic wave that reaches supersonic speeds and produces a sharp pressure gradient at the leading edge. Electrohydraulic systems generate this wave inside the applicator and deliver it as a coherent, high-energy impulse.
Radial pressure wave: A lower-velocity pressure wave that disperses energy superficially and primarily creates mechanical perturbations near the skin surface.

Key physiological effects of true shockwave:

Cell membrane mechanotransduction: The rapid pressure shift causes a transient change in cell membrane permeability, initiating signaling cascades.
Angiogenesis: Upregulation of pro-angiogenic factors (e.g., VEGF) stimulates the formation of both small and large vessels, improving perfusion to hypoxic or degenerated tissues.
Inflammation modulation: Downregulation of NF-κB pathways and altered cytokine profiles can help shift chronic inflammatory states toward resolution.
Tissue remodeling: Stimulation of tenocytes, fibroblasts, and osteoblasts enhances matrix turnover, collagen alignment, and bone healing.
Analgesic neuromodulation: Changes in peripheral nociceptor sensitivity and local neuropeptide signaling can reduce pain over time without neurodestructive effects.

Why speed and waveform matter:

The steep pressure gradient of a true shockwave produces a shearing force at the cell membrane, which initiates the biological cascade (mechanotransduction).
Devices that produce sound waves that converge into a shockwave only outside the applicator may have a shorter effective burst and require precise targeting to avoid under- or overdosing tissue.
Electrohydraulic devices generate a shockwave within the applicator, providing a consistent, therapeutic energy profile that can reach deeper targets (often cited as up to approximately 12 cm, depending on tissue, coupling, and parameters).

Electrohydraulic Versus Electromagnetic/Piezoelectric: Practical Differences

There are several ways to generate shockwaves:

Electrohydraulic: Two electrodes create a spark in water, producing a cavitation bubble; the leading edge of the bubble is the shockwave. This is often considered a gold standard by clinical shockwave societies due to stable energy delivery and deeper penetration.
Electromagnetic: A magnetic coil accelerates a membrane or projectile; a shockwave forms as sound waves converge.
Piezoelectric: Arrays of crystals emit waves that focus and converge to create a shockwave in a focal zone.

Clinical implications:

Electrohydraulic systems typically deliver a full-energy shockwave at the applicator exit, reducing the “gap” between the device and the therapeutic zone.
Convergent systems (electromagnetic, piezoelectric) can be effective but may have narrow focal zones, shorter burst durations, and require meticulous targeting and tip selection.
The patient experience can differ: a broader energy distribution tends to be more comfortable, enabling higher-dose delivery without anesthesia.

True Shockwave Versus Radial Pressure Waves: Mechanisms And Outcomes

It is common to see radial devices marketed under “shockwave” branding. Mechanistically, radial devices:

Produce pressure waves at sub-shock speeds.
Disperse energy superficially, relying on microtrauma to induce reactive hyperemia and local neurogenic effects.
Can be uncomfortable, and their therapeutic depth is generally limited.

Where radial can be useful:

Short-term pain relief in superficial soft tissue conditions.
Adjunct to manual therapy for myofascial trigger points.
Situations requiring cost-effective, quick, superficial treatment.

Limitations:

The durability of results may degrade over months in chronic degenerative conditions, as suggested by independent patient-reported outcome data comparing radial and true shockwave approaches.

The Two-Wave Advantage: Focused And Broad Focus Delivery

With electrohydraulic systems, particularly those using parabolic reflectors, two effects can be achieved:

Primary focused wave: Laser-pointer-like focal energy reaching deeper tissue targets.
Broad focus column: Recovered energy from the expanding cavitation bubble is redistributed, creating a larger therapeutic zone.

Why this matters:

A larger treatment volume can address complex pain generators that are regionally interdependent (e.g., plantar fascia, intrinsic foot muscles, tibialis posterior, and soleus).
Faster treatment times due to broader coverage.
Reduced technician dependency because biofeedback cues and broader zones make precision less brittle.
Improved comfort, allowing higher energy without anesthesia.

Biofeedback: The Patient Guides The Map

One practical advantage of shockwave therapy is patient biofeedback during treatment:

Healthy tissue feels like gentle tapping.
Inflamed or damaged tissue feels sharply distinct, allowing clinicians to map hotspots and functional pain generators.
This reduces guesswork and allows real-time tailoring of energy density, pulse number, and coverage.

Sports Medicine Use Case: Rapid Return-To-Play

Consider an athlete with an adductor strain. Typical recovery for moderate strains is often 6–10 weeks, depending on grade and reinjury risk. Athletes treated with true shockwave combined with integrative rehab can sometimes return in 3–4 weeks when:

Deep perfusion is improved via angiogenesis and vasodilation.
Pain is modulated without masking protective reflexes.
Tissue remodeling is supported with eccentric loading, neuromuscular re-education, and fascia mobility during the subacute window.

Orthopedic Insights From Elite Sports

Orthopedic specialists serving NBA and NFL athletes frequently use shockwave for:

Bone edema
Slow-healing fractures
Post-operative nonunion risk
Soft tissue tendinopathies

These clinicians report greater patient tolerance with true shockwave devices that deliver comfortably, thereby allowing higher-energy dosing without anesthesia and consistent day-to-day clinic throughput. This aligns with the published literature demonstrating the utility of shockwaves in bone and tendon biology through angiogenesis and mechanotransductive signaling.

How Integrative Chiropractic Care Fits The Model

Shockwave therapy works best in an integrative framework that addresses mechanical, neurophysiological, metabolic, and behavioral dimensions. In my clinic, we approach musculoskeletal problems through the following pillars:

Biomechanics and joint mechanics:
- Correct regional alignment: In plantar fasciitis, foot pronation, tibial internal rotation, and hip mechanics create downstream overload on the plantar fascia. Chiropractic adjustments to the subtalar joint, midfoot, and pelvis can redistribute load and normalize gait.
- Improve segmental mobility: Thoracolumbar stiffness can degrade shock absorption; lumbar-pelvic adjustments support kinetic chain efficiency.
Fascial continuity and neuromuscular coordination:
- Fascia connects the foot to the calf, hamstrings, and the lower back via myofascial chains. SoftWave improves perfusion and tissue pliability, while chiropractic soft-tissue work promotes gliding and hydration of the fascial planes.
- Focused motor control drills retrain the intrinsic foot muscles, the tibialis posterior, and the hip abductors to prevent recurrence.
Load management and graded exposure:
- Implement eccentric loading and isometric pain-modulating holds to enhance collagen remodeling in tendons under safe strain.
- Use return-to-sport progressions based on pain response, strength benchmarks, and functional testing (e.g., single-leg hop, Y-balance).
Anti-inflammatory nutrition and recovery biology:
- Encourage omega-3 fatty acids, polyphenols (curcumin, quercetin), vitamin D, magnesium, and targeted collagen peptides to support connective tissue health.
- Address sleep architecture and stress modulation, which influence cytokine profiles and healing velocity.
Footwear, orthotics, and surface management:
- Consider temporary orthotic support to unload the plantar fascia during high-volume training weeks.
- Optimize shoe geometry (heel-to-toe drop, midfoot stiffness) to improve force distribution.

Clinical Observations From My Practice

Across multiple musculoskeletal conditions, I observe:

Immediate reductions in pain scores following shockwave, especially when combined with regional adjustments and fascial mobilization.
Durability improves when patients receive structured motor retraining and metabolic support.
In tendinopathies (patellar, Achilles, gluteal), pairing shockwave therapy with progressive eccentric loading and coaching on stride or jump mechanics yields superior outcomes compared with passive care alone.
For bone edema and stress reactions, true shockwave paired with relative rest, calcium/vitamin D, and careful return-to-impact criteria often accelerates readiness while reducing reinjury risk.

True Shockwave And Biologics: Rational Combinations

Shockwave interacts with biologic therapies thoughtfully:

Same-day approach:
- Use shockwave to reduce pain and increase perfusion; perform PRP or cellular biologic injection afterward. Patients often tolerate injections better due to the immediate analgesic effects.
Pre-injection priming:
- Deliver shockwave 2–3 days prior to biologic injection to enhance vascularity and cellular signaling, potentially improving biologic distribution and response.
Diagnostic reinforcement:
- Use shockwave biofeedback to identify pain generators with a witness present; document patient responses to localize pathology and justify targeted biologic therapy.

Why each protocol makes sense:

Shockwave-induced vasodilation and angiogenic signaling can facilitate biologic dispersion and nutrient delivery.
Modulation of inflammation reduces hostile cytokine environments that can degrade biologic efficacy.
Analgesia without anesthesia preserves protective neuromuscular control, reducing the risk of overloading post-injection immediately.

Device Selection And Practical Considerations

If you are evaluating devices:

Prioritize true shockwave generation with consistent energy delivery and sufficient depth.
Evaluate energy distribution patterns: A broad focus column plus focus offers versatility for both diffuse and focal pathologies.
Consider patient comfort: Devices that deliver higher energy comfortably improve compliance and throughput.
Assess training and workflow: Systems that are biofeedback-guided and easy to delegate to trained staff can streamline care without compromising safety.

Clinic Workflow And Patient Experience

Shockwave sessions in my clinic typically last 10–15 minutes. We:

Conduct a focused functional exam and pain provocation tests.
Use biofeedback mapping to guide energy dosing.
Immediately follow with manual therapy, chiropractic adjustments, and targeted exercises to lock in gains.
Provide home care protocols: gentle mobility, isometric holds, footwear guidance, and nutrition.
Track outcomes using PROMs (pain scales, LEFS, VISA-A for Achilles, etc.) to quantify progress and justify care plans.

Cost And Access

Shockwave therapy is often a cash-based service, though some regions and payers may offer limited reimbursement for specific indications. In my experience, patients value:

Rapid relief
Non-invasive approach
Fewer injections
Evidence-backed tools

Transparent pricing, clear expectations, and outcome tracking build trust and encourage adherence.

Use Cases: Plantar Fasciitis, Tendinopathy, And Bone Edema

Plantar fasciitis:
- Address degenerative microtears and fibrosis with shockwave-induced angiogenesis and matrix remodeling.
- Integrate foot mechanics correction, calf flexibility, and eccentric loading.
- Typical plan: 3–6 sessions over 4–8 weeks, tailored by pain and function.
Achilles and patellar tendinopathy:
- Target mid-substance degeneration and enthesis changes using focused energy.
- Pair with tempo-controlled eccentrics and isometric protocols (45–60 second holds for pain modulation).
Bone edema and slow-healing fractures:
- Use shockwave to stimulate osteogenesis and microcirculation, while managing load and nutrition.
- Coordinate with imaging and orthopedic oversight for safe progression.

Physiological Underpinnings: Why These Techniques Work

Mechanotransduction: Shockwave applies mechanical stress that cells convert into biochemical signals—a core regenerative cue in tendon and bone.
Angiogenesis and perfusion: Chronic pain is often a story of oxygen debt. Improving microvascular flow restores the redox balance, supports ATP production, and accelerates matrix repair.
Inflammation resolution: Many chronic conditions are stuck in an immune loop of low-grade inflammation. Shockwave can shift cytokine profiles toward resolution, enabling fibroblasts and tenocytes to remodel effectively.
Neuromodulation: Pain reduction without nerve ablation allows normal motor learning and movement quality to return during rehab—a safer, smarter approach.

Implementation Roadmap For Clinicians

Assess:
- Identify pain generators via functional testing and biofeedback mapping.
- Consider imaging for bone edema or complex tendinopathy.
Plan:
- Select energy levels and pulse counts based on tissue depth and patient tolerance.
- Integrate chiropractic adjustments, manual therapy, and exercise on the day of.
Deliver:
- Keep sessions short, progressive, and guided by patient feedback.
- Use a broad focus for regional complaints and focused energy for pinpoint lesions.
Reinforce:
- Provide home protocols, nutrition plans, and sleep hygiene.
- Schedule follow-ups and measure outcomes with standardized scales.
Combine when indicated:
- Coordinate with PRP or other biologics using same-day or pre-injection priming.
- Document responses to build a data-informed case, improving patient consent and expectations.

What Patients Feel And How We Adjust

Early sessions may include transient soreness at hot spots; this is expected and short-lived.
Most patients feel immediate lightness or reduced pain, making subsequent rehab easier.
If discomfort increases, we adjust energy or coverage while maintaining therapeutic intent.

Safety And Contraindications

Avoid direct application over malignancy, active infection, or open wounds.
Caution with pregnancy over the abdomen/low back.
Coordinate with cardiology for anticoagulated patients near deep vascular structures.
For acute complete tendon ruptures, shockwave is not a substitute for surgical repair; we use it post-operatively when cleared.

A Real-World Example: Return-To-Sport Strategy

For a competitive court-sport athlete with adductor strain:

Week 0–1:
- Shockwave to the adductor complex and pelvic attachments.
- Chiropractic adjustments for pubic symphysis and sacroiliac joints.
- Isometric adductor holds, gentle mobility, and anti-inflammatory nutrition.
Week 2–3:
- Progressive eccentric adductor loading and lateral movement drills.
- Continue shockwave as symptoms guide; expand coverage to hip flexors and gluteal stabilizers.
- Gait and stride mechanics corrections.
Week 3–4:
- Introduce change-of-direction, acceleration/deceleration, and reactive drills.
- Clearance based on pain-free function, strength symmetry, and field tests.

In practice, this integrative plan frequently compresses recovery timelines while preserving tissue integrity.

Where To Learn More

For clinicians and patients interested in exploring shockwave research, professional societies and independent registries offer robust resources. You will find clinical guidelines, mechanisms, and outcome data across tendon, bone, and soft tissue conditions.

Training, Support, And Workflow Integration

Clinics that implement shockwave successfully typically:

Receive hands-on training from experienced providers.
Adopt biofeedback mapping in daily workflow.
Leverage marketing assets to educate their community and referrers.
Track PROMs and share outcomes in peer forums to refine protocols.

Closing Thoughts: Bringing Science, Skill, And Compassion Together

Patients with chronic pain taught me a simple truth: the body is eager to heal when given the right signals. SoftWave shockwave therapy delivers those signals powerfully and safely. When combined with integrative chiropractic care, targeted exercise, and smart biologics, the results are often transformative. Patients do not need to rely solely on injections or tolerate long downtimes. They need a coherent, evidence-informed plan that respects physiology, mechanics, and lived experience.

If you are struggling with chronic pain or you are a clinician looking for a better way, consider a thoughtful shockwave-based approach integrated with chiropractic biomechanics, fascia care, and functional medicine. It is not just about feeling better today—it is about building durable health for tomorrow.

References

International Society for Medical Shockwave Treatment (ISMST): Clinical guidelines and resources (n.d.). Clinical guidance on shockwave mechanisms, indications, and safety.
SoftWave Therapy: Research library and compendium (n.d.). Device-specific studies, international compendium, and clinical applications.
ChiroMed: Clinical observations and integrative care insights by Dr. Alexander Jimenez (n.d.). Practice-based evidence and case-informed protocols.
Dr. Alexander Jimenez, LinkedIn professional profile: Sports medicine and functional chiropractic integration (n.d.). Professional background and clinical updates.

May 11, 2026

Ultrasound Therapy Benefits and Uses For The Musculoskeletal System

Find out how ultrasound therapy provides effective solutions for chronic musculoskeletal pain and joint issues.

Abstract

As a clinician with a diverse background in chiropractic, nursing, and functional medicine, I have dedicated my career to integrating the most advanced, evidence-based tools into patient care. This post explores the transformative role of musculoskeletal ultrasound (MSKUS), a powerful, real-time imaging modality that has revolutionized the way we diagnose and treat soft-tissue injuries. We will embark on a journey through the sonographic appearance of various tissues—tendons, muscles, cartilage, ligaments, and nerves—understanding their unique visual signatures. I will share insights from leading researchers and practical clinical pearls from my own practice on interpreting these images, including the critical concept of anisotropy. Furthermore, we will delve into proper probe handling techniques for both diagnostic and procedural applications, emphasizing methods that set clinicians up for success. Finally, I will explain how these advanced diagnostic capabilities integrate with a holistic, integrative chiropractic approach, enabling more precise, effective, and patient-centered treatment plans that support true healing.

Understanding the Language of Ultrasound: Echogenicity Explained

In my practice, I often refer to musculoskeletal ultrasound as a “glorified flashlight” that allows us to peer directly into the body’s anatomy in real time. But to understand what we’re seeing, we must first learn its language. The fundamental concept is echogenicity, which describes how tissues reflect ultrasound waves.

Hyperechoic: Tissues that appear bright white on the screen. These structures, like bone, are dense and reflect most ultrasound waves to the probe.
Hypochoic: Tissues that appear dark gray. These structures, like muscle or fluid, absorb more ultrasound waves and reflect fewer.
Anechoic: Tissues that appear completely black. These are typically fluid-filled structures, such as cysts or bursae, that transmit almost all sound waves.
Isoechoic: Tissues that have a similar brightness or echotexture to adjacent structures.

Pattern recognition is the cornerstone of interpreting ultrasound images. Each tissue type has an expected appearance, and deviations from this norm can signal pathology.

Sonographic Signatures of Key Musculoskeletal Tissues

Let’s explore what healthy tissues look like under the lens of an ultrasound probe.

Tendons: The Body’s Strong Cords

Tendons are the strong, fibrous cords that connect muscle to bone. On ultrasound, a healthy tendon has a classic appearance: it’s hyperechoic (bright) and displays a distinct fibrillar pattern—think of it as a tightly packed bundle of cables or parallel stripes.

For example, when we look at the patellar tendon in a long-axis view (aligned with the tendon), we expect to see a bright, organized, striped pattern. Beneath it, we can identify other structures, such as the infrapatellar fat pad (which has a more wavy, less organized appearance) and the hyperechoic surfaces of the patella and tibia. Recognizing this norma, fibrillar architecture is crucial because when a tendon is injured (tendinosis or a tear), it loses this organization, thickens, and appears more hypoechoic (darker).

Muscles: The Engines of Movement

Muscle tissue presents a more complex, mixed-echogenicity pattern. It is generally hypoechoic compared to the bright white of bone. However, within the muscle belly, you’ll see hyperechoic strands of connective tissue, known as the perimysium, which encase the muscle fascicles. This gives healthy muscle a “marbled” or “feathery” appearance.

When viewing a muscle like the bicep or deltoid over the humerus, you can see the dark muscle tissue contrasted against the bright cortical line of the bone. You can even appreciate its structure, tapering towards its tendinous insertion. This visual information helps us identify muscle strains, tears, or atrophy.

Cartilage: Smooth Surfaces and Tough Cushions

Cartilage is a critical tissue, and ultrasound helps us differentiate between its two main types:

Hyaline Cartilage: This is the smooth, glassy cartilage that covers the ends of bones within a joint, allowing for low-friction movement. On ultrasound, it appears as a distinct, thin, hypoechoic (dark) line sitting directly on the bright, hyperechoic bone surface. A great example is viewing the posterior aspect of the humeral head in the shoulder joint.
Fibrocartilage: This is a tougher, more fibrous type of cartilage found in structures like the meniscus of the knee or the labrum of the shoulder and hip. Unlike hyaline cartilage, fibrocartilage is hyperechoic (brighter) and has a more triangular or wedge-shaped appearance. On the shoulder, you can clearly distinguish the bright, triangular labrum from the dark, linear hyaline cartilage on the humeral head.

Ligaments: The Stabilizers

Ligaments, which connect bone to bone, look very similar to tendons on ultrasound. They are also hyperechoic and have a fibrillar, striated pattern. The key difference is that ligaments are typically more compact and densely packed than tendons.

The true power of ultrasound in evaluating ligaments comes from its real-time, dynamic capabilities. The best way to confirm you are looking at a ligament is to trace it from one bony attachment to another. If it originates from or inserts into a muscle, it’s a tendon. With ligaments such as the Medial Collateral Ligament (MCL) of the knee, we can perform a stress test under direct visualization. By applying a valgus force to the knee, we can watch the ligament in real time to see if there is any “gapping” or separation of its fibers.

A report might read: “The linear probe was placed over the medial aspect of the knee, and the MCL was visualized in a long-axis view. Upon real-time valgus stress, there was observable gapping of the mid-substance fibers with surrounding hypoechoic fluid, consistent with a grade 2 sprain.” This level of detail is impossible with a static MRI.

Nerves: The Body’s Electrical Wiring

Nerves have a unique and fascinating appearance on ultrasound, often described as a “honeycomb” in short-axis (cross-section) view. This pattern is created by the hypochoic nerve fascicles (the bundles of nerve fibers) surrounded by the hyperechoic epineurium (the connective tissue sheath).

In a long-axis view, the nerve can look like a bundle of parallel “railroad tracks,” though this view is often less distinct than the honeycomb cross-section. A clinical pearl I share with my students is that nerves are often easier to spot when you scan. The distinct honeycomb pattern moves through the surrounding tissue, catching your eye more readily than the linear patterns of tendons or muscles. The carpal tunnel is the classic location to visualize this, as the median nerve’s honeycomb structure stands out clearly against the adjacent flexor tendons in the forearm.

The Challenge of Anisotropy: A Critical Pitfall to Avoid

One of the most important concepts in MSKUS is anisotropy. This phenomenon occurs when the ultrasound beam is not perfectly perpendicular (at a 90-degree angle) to the structure being imaged, particularly tendons and ligaments. When the beam hits the tissue at an angle, the sound waves are reflected away from the probe instead of back to it. This lack of returning signal causes the normally bright, hyperechoic tissue to appear artifactually hypochoic, or dark.

Why is this so critical? Because a tendon tear also appears as a hypoechoic defect. Anisotropy can mimic pathology, leading to a false-positive diagnosis.

Here’s how we differentiate:

Prove the Pathology: If you see a dark spot in a tendon, like the supraspinatus tendon at its insertion on the humerus, you must prove it’s real.
Toggle the Probe: Carefully “heel-toe” or “toggle” the probe to ensure you are perfectly perpendicular to the tendon fibers at that exact spot.
Observe the Change: If the dark spot disappears and brightens when you adjust the probe angle, it indicates anisotropy. If the dark spot remains dark no matter how you angle the probe, it is more likely to be true pathology, such as tendinosis or a tear.

In my practice, I live by the mantra taught in orthopedic surgery: “One view is no view.” I always confirm a suspected finding from multiple angles, in both long and short-axis views, and correlate it with a dynamic assessment and the patient’s physical exam. This meticulous approach is what separates a novice from an expert operator and ensures diagnostic accuracy.

Mastering the Tool: Proper Probe Handling Techniques

Ultrasound is operator-dependent. Your skill in handling the probe directly impacts the quality of your images and the accuracy of your diagnosis.

The Tripod Grip for Diagnostic Scanning

For diagnostic imaging, stability and fine control are paramount. The “death grip,” where you wrap your whole hand around the probe, is unstable and limits fine motor control. Instead, we use the tripod technique.

Hold the probe like a pencil, using your thumb and index finger for control.
Brace your remaining fingers (pinky, ring, and/or middle finger) on the patient’s skin.
This creates a stable base, allowing subtle, precise movements such as sliding, toggling (heel-toe), and rotating to remain perpendicular to curved structures and eliminate anisotropy.

Your hand should be in contact with the patient. This is a more connected, controlled experience that allows you to feel the anatomy as you visualize it.

Modifying the Grip for Procedural Guidance

When performing an ultrasound-guided injection, the grip must change. Holding the probe with your fingers wrapped around it can physically block your needle’s path. For this reason, I advocate for holding the probe by its edges, which keeps your fingers clear of the sterile field and the needle’s intended path.

In-Plane Technique: For this approach, in which the needle is inserted parallel to the probe’s long axis and visualized along its entire length, a pencil-like grip is often effective.
Out-of-Plane Technique: In this approach, where the needle is inserted perpendicular to the probe and appears as a bright dot in cross-section, holding the probe by its edges provides the necessary space.

The key is to be facile, comfortable moving the probe in different ways for different tasks. Pre-planning your procedure is essential. My protocol is simple:

Find the Target: Use your scanning skills to locate the exact anatomical target.
Stay Perpendicular: Position the probe directly over the target, perpendicular to the skin. This simplifies your needle trajectory.
Bring Tip to Target: Once you have a clear, stable view of your target, you can confidently guide your needle tip precisely where it needs to go.

This methodical approach minimizes “searching” for the needle or the target, making procedures faster, safer, and more successful.

Integrative Chiropractic Care and Ultrasound Synergy

So, how does this high-tech imaging fit into a chiropractic and functional medicine framework? Perfectly.

At our clinic, we don’t just treat symptoms; we seek to understand and correct the underlying biomechanical and physiological dysfunction. MSKUS is an invaluable tool in this process.

Precision Diagnosis: Before I perform a chiropractic adjustment or recommend a course of rehabilitative exercise, I want to know exactly what tissue is injured. Is that shoulder pain from a rotator cuff tear, biceps tendinopathy, or bursitis? Ultrasound tells me instantly, allowing me to tailor my treatment. For instance, if I identify a partial tear in the supraspinatus tendon, I can modify my spinal and extremity adjustments to avoid stressing the injured tissue and instead focus on improving scapular mechanics to offload the tendon.
Guiding Soft Tissue Therapies: Many of our treatments involve soft-tissue mobilization, such as Active Release Technique (ART) or the Graston Technique. Ultrasound allows me to visualize fibrotic adhesions or scar tissue and specifically target these areas, making the treatment more efficient and effective.
Monitoring Healing: Ultrasound provides objective evidence of tissue healing. We can track the reduction of inflammation, the reorganization of collagen fibers in a healing tendon, or the decrease in fluid within a bursa over time. This helps us advance the patient’s rehabilitation protocol based on actual tissue physiology rather than just subjective pain reports.
Patient Education: Showing a patient a real-time image of their injury is incredibly powerful. When they can see the inflamed bursa or the tear in their tendon, it enhances their understanding and improves their adherence to the treatment plan. It transforms the abstract concept of their injury into something tangible.

Ultimately, musculoskeletal ultrasound elevates the practice of integrative chiropractic care. It bridges the gap between a physical exam and a definitive diagnosis, allowing a level of precision previously unattainable in clinical settings. It helps us create highly specific, evidence-based treatment plans that address the root cause of a patient’s pain and dysfunction, accelerating their path back to optimal health and function.

As of May 2nd, 2026, the technology continues to evolve, but its core value remains: it is a safe, dynamic, and profoundly insightful tool that, in the hands of a skilled operator, can truly transform patient outcomes.

References

Jacobson, J. A. (2017). Fundamentals of Musculoskeletal Ultrasound (3rd ed.). Elsevier.

McNally, E. G. (2014). Practical Musculoskeletal Ultrasound (2nd ed.). Elsevier.

The Ultrasound Site. (n.d.). Musculoskeletal Ultrasound. Retrieved from https://www.theultrasoundsite.co.uk/

Ultrasound For Movement Disorders. (n.d.). MSK Resources. Retrieved from https://www.ultrasoundformovementdisorders.com/

SEO Tags: Musculoskeletal Ultrasound, MSKUS, Integrative Chiropractic, Dr. Alexander Jimenez, Echogenicity, Anisotropy, Tendinopathy, Ligament Sprain, Nerve Entrapment, Ultrasound-Guided Injections, Functional Medicine, Chiropractic Care, Sports Medicine, Diagnostic Imaging, Soft Tissue Injury, El Paso Chiropractor, Probe Handling

May 11, 2026

Chiropractic Shockwave Therapy for Pain and Healing

Radial vs. Focused Approaches, Physiological Mechanisms, Clinical Protocols, and Practical Considerations

Abstract

In this educational post, I share a clear, first-person overview of how shockwave therapy integrates into evidence-based chiropractic and advanced practice nursing care, explaining the differences between radial and focused shockwave systems, the underlying regenerative physiology, and how these modalities can be combined to optimize patient outcomes. I discuss FDA status, indications, dosing paradigms, and treatment sequencing for conditions such as tennis elbow, plantar fasciitis, whiplash-associated neck pain, and broader myofascial pain syndromes. I also outline practical details on device maintenance, session duration, patient experience, and cash-pay considerations, all framed within modern clinical research methods. Finally, I demonstrate how integrative chiropractic care, functional medicine, and rehabilitative protocols complement shockwave therapy to accelerate healing and restore function, supported by current literature and clinical observations from my practice.

Introduction: My Integrative Lens on Shockwave Care

As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I approach musculoskeletal care through an integrative model that blends chiropractic medicine, advanced practice nursing, functional medicine, and rehabilitative sciences. In recent years, I have incorporated acoustic shockwave technologies to complement manual therapy, neuromuscular re-education, and metabolic optimization. The clinical question patients and colleagues often ask is simple: how do these devices work, which type is appropriate, and how do we combine them within a patient-centered care plan?

In this post, I take you through a straightforward journey:

What shockwave therapy is and how it differs between radial and focused systems
The physiological basis of tissue regeneration triggered by acoustic waves
Why combining radial and focused treatments can produce synergistic results
FDA status, indications, session parameters, and maintenance
Evidence-based protocols and how we titrate energy levels using real-time patient feedback
How integrative chiropractic care and functional medicine enhance outcomes
Practical notes on reimbursement, patient materials, and clinical communication

Throughout, I reference contemporary literature and share clinical observations from my practice, highlighting the care pathways we use at ChiroMed and those we use in collaboration with broader interdisciplinary networks.

Shockwave Therapy Basics: What It Is and Why It Matters

Shockwave therapy delivers high-pressure acoustic waves into target tissues to stimulate the body’s innate regenerative and anti-inflammatory mechanisms. The field evolved from lithotripsy, originally used to break kidney stones. Clinicians then noticed surrounding soft tissues exhibited improved quality post-treatment, spurring research into orthopedic and sports applications.

Key distinctions:

Radial shockwave disperses energy from the skin surface and fans out through the tissue to a depth of roughly 6 cm, favoring superficial tendons and large muscle groups.
Focused shockwave converges energy at a precise focal point up to ~12.5 cm deep, ideal for tendons, bone, ligaments, and deep joint pain.

These mechanical stimuli produce controlled microtrauma, which is central to the therapeutic cascade. Rather than damaging tissues, the microtrauma acts as a signal—prompting targeted neovascularization, growth factor upregulation, and cellular recruitment necessary for remodeling and repair.

Radial vs. Focused Shockwave: Energy Distribution and Clinical Targeting

The difference between radial and focused shockwave lies in energy distribution:

Radial: Highest energy at the skin; wavefront dissipates as it travels inward; broad field engagement of fascia and muscle.
Focused: Energy converges at depth; highly pinpoint targeting of the primary pain generator or structural lesion.

In practice, I often layer these modalities in a single session:

Use radial shockwave across affected myofascial chains (e.g., forearm flexors/extensors and biceps in lateral epicondylopathy) to reduce global tone, address trigger points, and improve tissue pliability.
Follow with focused shockwave directly over the primary lesion (e.g., degenerative extensor tendon insertion at the lateral epicondyle) to catalyze tissue-specific healing responses.

This dual approach respects both the regional interdependence of musculoskeletal pain and the necessity of site-specific regenerative signaling.

Physiological Underpinnings: From Microtrauma to Regeneration

Why does controlled acoustic microtrauma work? The physiology unfolds across several interconnected domains:

Mechanotransduction: Acoustic waves deform cellular membranes and extracellular matrix (ECM). Integrins, stretch-activated ion channels, and cytoskeletal elements transduce mechanical inputs into biochemical signals that regulate gene expression and protein synthesis (Wang, 2012).
Neovascularization and angiogenesis: Shockwave stimulates vascular endothelial growth factor (VEGF), eNOS, and related pathways, increasing capillary density and improving perfusion to ischemic or chronically degenerated tissues (Hausdorf et al., 2011).
Inflammatory modulation: Microtrauma induces a controlled acute-phase response, converting a chronic, low-grade inflammatory milieu into a time-limited acute state with organized repair—resetting stalled healing cycles typical of tendinopathies (Rompe et al., 2009).
Fibroblast activation and collagen remodeling: Enhanced fibroblast activity and collagen turnover shift tissue architecture from disordered Type III collagen toward more aligned, load-bearing Type I collagen, improving tensile strength (Wang et al., 2003).
Nociceptive effects: Shockwave may modulate pain via hyperstimulation analgesia, substance P depletion at sensory nerve endings, and activation of descending inhibitory pathways. Clinically, patients often report immediate analgesia and improved range of motion after a session—effects that partially recede within ~72 hours before consolidating with serial treatments (Notarnicola & Moretti, 2012).
Stem/progenitor cell recruitment: Acoustic cues can enhance mesenchymal stromal cell migration and differentiation in preclinical models, supporting tendon-bone interface healing and cartilage support under specific dosing conditions (Chen et al., 2014). While human data are still evolving, these mechanisms inform dosing strategies.

In short, shockwave interrupts chronic pain physiology, converts it into an acute reparative state, and guides structural remodeling through repeat, appropriately titrated dosing.

Immediate Relief vs. Long-Term Remodeling: Setting Expectations

One hallmark of clinical shockwave is the rapid analgesic effect many patients feel upon standing after the session. Patients often say that the arm, heel, or neck “feels amazing” with improved range of motion. However, I emphasize that this is step one. Over the next ~72 hours, some symptoms transiently return. With each subsequent session, the recurrence is diminished, reflecting cumulative tissue regeneration and functional adaptation.

We schedule shockwave in series—common patterns include 4–6 sessions spaced 5–10 days apart, depending on indication, tissue response, and comorbidities. The objective isn’t merely pain reduction; it’s structural and functional restoration.

FDA Status and Clinical Indications

Understanding regulatory status helps us communicate clearly and ethically:

Focused shockwave has FDA approval for chronic plantar fasciitis (e.g., ESWT/Focused ESWT devices).
Radial shockwave systems have FDA clearance for the treatment of chronic and acute musculoskeletal pain.

In practice, I consider shockwave for:

Plantar fasciitis/heel pain (focused primary; radial adjunct for calf/plantar fascia chain)
Lateral epicondylopathy (focused at tendon insertion; radial over forearm muscle groups)
Patellar tendinopathy and Achilles tendinopathy
Gluteal and proximal hamstring tendinopathies
Myofascial pain syndromes and trigger points
Hip abductor complex, rotator cuff tendinopathy, and selected bony stress responses under proper guidance
Neck pain and whiplash-associated disorders below the skull base—radial for global muscular tone; focused cautiously for deep facet/tendon interfaces when indicated

Note: Cranial applications remain contraindicated in the US at present, though ongoing investigational work in Europe is underway.

Session Design, Dosing, and Patient Experience

We aim for treatment sessions around 10 minutes when combining modalities:

Radial shockwave: ~5 minutes, commonly 2,500–3,000 pulses per session
Focused shockwave: ~5 minutes, with pulse counts adapted to the device and indication

The handpiece interfaces allow real-time pulse tracking, energy adjustments, and preset stops. I titrate energy using patient feedback to maintain a therapeutic sensation of roughly 5–6 out of 10—intense enough to engage the physiology, but not so strong as to provoke guarding or undue distress. Because shockwave is diagnostic in practice, I use palpable landmarks, ultrasound when appropriate, and patient-reported tenderness to find and follow the pain generators.

Sound levels: Radial devices are louder (mini jackhammer sound), whereas focused devices are quieter. Modern systems have improved acoustic dampening relative to older platforms.

Safety and Contraindications

Avoid treatment over active infection, malignancy, or open growth plates (pediatric considerations).
Exercise caution over vascular or neural bundles, and in patients with coagulopathies or on anticoagulants.
Cranial applications are not cleared in the US; limit upper cervical work to below the skull base.
Dose conservatively in severe neuropathy or altered pain processing syndromes, titrating by feedback.

Device Maintenance and Practical Operations

For reliable performance, maintenance is straightforward:

Radial shockwave: Replace the guide tube and bullet approximately every 1,000 treatments (~2 million pulses for the pair). Revision kits include two bullets and two guide tubes. Handpiece notifications prompt replacement; providers can perform an easy swap via video guidance or live support.
Focused shockwave: Replace the coil after around 2 million pulses (~1,000 treatments). The handpiece is typically overnighted to service for same-day repair and return, with scheduling tips to minimize clinic downtime.

Applying Shockwave in Personal Injury and Neck Care

For whiplash-associated cases, I use an integrative protocol:

Radial shockwave across hypertonic upper trapezius, levator scapulae, scalenes, and paraspinals below the skull base to normalize tone and reduce myofascial trigger points.
Focused shockwave when indicated over facet capsule areas or tendinous insertions with precise dosing, guided by palpation and, when appropriate, ultrasound. This combination reduces guarding and prepares tissues for manual therapy and motor control retraining.

Integrative Chiropractic Care: Layering Modalities for Superior Outcomes

Shockwave is not a standalone cure—it is most powerful when integrated:

Chiropractic adjustments: Once radial shockwave reduces guarding and focused shockwave modulates deep nociception, spinal and extremity adjustments can be delivered with less resistance and greater carryover.
Neuromuscular re-education: I pair shockwave with targeted isometrics in early phases, then eccentric loading (e.g., Alfredson protocol variants) to align collagen fibers and reinforce tensile strength in tendons.
Fascia-focused care: Post-shockwave, instrument-assisted soft-tissue mobilization or myofascial release can remodel ECM cross-links while perfusion is elevated.
Functional medicine support: Optimize micronutrients (Vitamin C, collagen peptides, magnesium), sleep, glycemic control, and inflammation (addressing omega-3/6 balance) to support collagen synthesis and tissue repair. I monitor metabolic markers when needed for stubborn cases.

Clinical Observations from My Practice

In my clinics (see ChiroMed and my professional LinkedIn profile), I observe consistent patterns:

Plantar fasciitis: Focused shockwave over the medial calcaneal attachment, with radial shockwave across the posterior chain (gastrocnemius/soleus and plantar fascia). Patients often report first-step pain reduced after session two, with functional gains consolidated by week 4–6.
Lateral epicondylopathy: Radial shockwave to forearm compartments reduces tone; focused shockwave to the common extensor tendon origin accelerates pain resolution. I incorporate eccentric wrist-extensor exercises and ergonomic coaching to achieve sustained outcomes.
Cervical myofascial pain: Radial shockwave to the upper quarter reduces headaches and neck stiffness, especially when combined with scapular stabilization and cervical motor control drills.
Achilles tendinopathy: Dose-focused sessions at the midportion or insertion; radial shockwave reverberates across calf muscle fascia. Eccentrics and load management remain essential.

Patients report immediate relief, with a transient return of symptoms, followed by decreasing recurrence and improved tissue quality across a series. These patterns align with the known biology of shockwave-induced remodeling and the literature’s outcome curves.

Evidence-Based and Research Methods

Modern shockwave research spans randomized controlled trials, meta-analyses, and biomechanical studies. Core findings:

Plantar fasciitis: Multiple RCTs support the superiority of focused ESWT over sham or conservative care for chronic cases, improving pain and function (Gerdesmeyer et al., 2008).
Lateral epicondylopathy: ESWT demonstrates clinically meaningful pain reduction and improvements in grip strength, with particular benefit in chronic cases (Rompe et al., 2004).
Tendinopathy biology: Mechanotransduction and angiogenic responses underlie the observed improvements (Wang, 2012), while studies show reductions in substance P and CGRP in tendon nociceptors, which explain rapid analgesia (Maier et al., 2003).
Myofascial pain: Radial shockwave can reduce trigger point tenderness and improve functional measures compared to baseline (Cagnie et al., 2013).

Device technologies measure energy differently:

Electromagnetic focused systems commonly report energy in millijoules per square millimeter (mJ/mm²), reflecting the energy density at the tissue interface.
Electrohydraulic systems may report joules, which represent total burst energy, without the same normalized-area metric.

When interpreting literature, I align dosing models with energy density, frequency, and pulse counts, then correlate them with the clinical target and tolerance. This ensures translational fidelity from studies to practice.

Shockwave Protocol Design: Practical Steps

I standardize protocols while leaving room for individualized titration:

Intake: Assess pain generators, regional interdependence, activity demands, comorbidities, and prior response to care.
Planning:
- Radial shockwave: 2,500–3,000 pulses across related muscle and fascial chains; start lower energy and titrate to a 5–6/10 therapeutic sensation.
- Focused shockwave: Target lesion with energy density consistent with literature for the indication; adjust based on tenderness and tissue depth.
Sequencing: Radial first to reduce tone; focused second to pinpoint the lesion.
Integration: Post-session gentle ROM, hydration guidance, and, within 24–48 hours, begin isometric or eccentric loading routines.
Series: Typically 4–6 sessions, each spaced by 5–10 days, with reevaluation after session 3 to confirm trajectory.
Outcomes: Pain VAS, functional scales (e.g., VISA-A for Achilles), and objective ROM/strength assessments.

Reimbursement, Cash-Pay, and Patient Communication

Shockwave is often positioned as a cash-pay modality in the United States. While some providers explore coding pathways, my stance focuses on transparency and value:

Present a clear series package (e.g., 4–6 sessions), with per-session rates typically between $250–$300, depending on the modality combination.
Use patient education materials—brochures, website pages, and scripts—to explain mechanisms, timelines, and expected post-treatment sensations.
Emphasize the functional ROI: fewer flare-ups, improved performance, reduced reliance on adjunct analgesics, and potential avoidance of more invasive interventions.

Patient Materials and Training

Comprehensive patient-facing content includes:

What shockwave is
Why we combine radial and focused treatments
What they will feel during and after a session
The importance of completing the series and participating in home exercise
Safety points and post-care instructions

Team training ensures consistent dose titration, proper handpiece handling, maintenance, and confident communication with patients.

Clinical Pearl: The 72-Hour Window

I counsel patients that immediate relief is common, but some symptoms may re-emerge within ~72 hours as acute signaling fades and tissue repair continues. This is normal. Over subsequent sessions, they notice a stepwise reduction in recurrence. Setting this expectation enhances adherence and satisfaction.

Integrative Outcomes: Faster Rehabilitation, Better Function

Within my integrative framework, shockwave accelerates:

Tissue readiness for manual therapy
Engagement with therapeutic exercise
Re-alignment of movement patterns
Return to work and sport

Functional medicine supports the biologic terrain for collagen synthesis, capillary formation, and sleep-dependent repair. Over time, patients experience not just symptom relief, but durable biomechanical improvements.

Closing Thoughts

Shockwave therapy—when properly dosed, sequenced, and integrated—bridges the gap between immediate analgesia and long-term tissue regeneration. By combining radial and focused approaches, aligning with current research, and embedding care within chiropractic, rehabilitative, and functional frameworks, we achieve meaningful, measurable outcomes. In my practice, these technologies have become a reliable part of restoring movement and reducing chronic pain, provided we honor the physiology and respect the patient’s lived experience.

References

Extracorporeal Shock Wave Therapy for Chronic Plantar Fasciitis: RCT Evidence (Gerdesmeyer, L., et al., 2008). The Lancet.
Evidence-Based Use of ESWT in Tendinopathies (Rompe, J. D., et al., 2004). Knee Surgery, Sports Traumatology, Arthroscopy.
Mechanotransduction and ESWT: Biological Mechanisms (Wang, C. J., 2012). International Orthopaedics.
Angiogenic Effects of Shockwave in Soft Tissue (Hausdorf, J., et al., 2011). European Surgery.
Shockwave Analgesia and Neuropeptide Modulation (Maier, M., et al., 2003). The American Journal of Sports Medicine.
Radial ESWT for Myofascial Pain: Clinical Outcomes (Cagnie, B., et al., 2013). Manual Therapy.
Tendon Collagen Remodeling Under ESWT (Wang, C. J., et al., 2003). The American Journal of Sports Medicine.
ESWT in Chronic Tendinopathy: Clinical Pathways (Rompe, J. D., et al., 2009). Postgraduate Medical Journal.

May 8, 2026

PRP Injections and Their Benefits for Osteoarthritis

Discover the potential of PRP injections for osteoarthritis treatment and its role in promoting healing and reducing inflammation.

Abstract

As a clinician dedicated to integrative and evidence-based care, I frequently encounter patients suffering from knee osteoarthritis (OA) who are seeking relief. The decision on which injectable treatment to use can be complex, involving a delicate balance of providing rapid pain relief, ensuring long-term joint health, and considering the patient’s individual needs and goals. In this educational post, I will guide you through the latest research on common intra-articular injections for knee OA. We will begin by examining the role and significant risks of corticosteroids, exploring why the medical community is moving toward alternatives. I will then introduce ketorolac, an NSAID injection, as a safer, fast-acting alternative for acute flares. We’ll delve into the science of hyaluronic acid (HA), or viscosupplementation, evaluating its potential for longer-term benefits and its current standing in clinical guidelines. Finally, we will explore the exciting and robust evidence supporting Platelet-Rich Plasma (PRP) as a treatment that not only manages pain but also shows promise as a disease-modifying therapy capable of delaying the need for surgery. Throughout this discussion, I will integrate my clinical observations and emphasize how an integrative chiropractic approach, focusing on biomechanics and holistic patient care, complements these advanced treatments to optimize outcomes for our patients.

Hello, I’m Dr. Alexander Jimenez. With my extensive background in chiropractic and functional medicine, holding titles such as DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST, my practice is rooted in a deep commitment to providing integrative care grounded in the latest scientific evidence. Today, I want to take you on a journey through the landscape of injectable treatments for knee osteoarthritis, a condition I see daily in my clinic. We’ll examine what the research tells us and how we can make the best choices for our patients.

Let’s begin with a common clinical scenario to frame our discussion.

A Common Clinical Scenario: The Acute Knee OA Flare

Imagine a 60-year-old woman who comes into my office with an acute flare-up of her right knee pain. She was diagnosed with mild osteoarthritis two years prior and had managed it well with physical therapy and weight loss. She remains quite active, but this current flare started after a bit more walking than usual. There was no specific injury or trauma. She presents with mild swelling, and her pain is most pronounced when using stairs. Her son’s wedding is just a week away, and she is understandably anxious, requesting an injection to improve her pain and mobility for the event.

On examination, she has a mild antalgic gait (walking with a limp to avoid pain), tenderness along the medial joint line, and a small effusion (swelling within the joint). Her X-rays confirm tricompartmental osteoarthritis with a Kellgren-Lawrence (K-L) grade of 2, which is considered mild to moderate.

So, we have a patient with an acute OA flare, no history of prior injections, and a significant life event approaching. What is the best way to help her? The most conventional response in many practices would be an intra-articular corticosteroid injection. But is that the right answer? My goal today is not to give you a single “correct” answer but to arm you with the evidence so you can make an informed decision, one that aligns with the principles of modern, evidence-based care.

The Double-Edged Sword of Corticosteroid Injections

Why Corticosteroids are so Common

There’s a clear reason why corticosteroids have been the go-to for decades. The primary driver of pain and swelling in an OA flare is synovial inflammation. Corticosteroids are potent anti-inflammatory agents. They work by:

Suppressing the infiltration of leukocytes (white blood cells) into the joint.
Decreasing the activity of local immune cells within the synovium (the soft tissue lining the joint).
Downregulating the expression of genes involved in the inflammatory cascade.

This powerful anti-inflammatory effect leads to decreased synovial membrane inflammation and a reduction in the effusion. The result is rapid pain relief, typically occurring within three to seven days. For our patient with the wedding next week, this timeline is very appealing. While oral NSAIDs or steroids could be considered, they carry significant systemic risks that an injection helps to minimize.

The Mounting Evidence Against Corticosteroids

Despite the short-term benefits, a growing body of evidence urges caution. There is significant concern for chondrotoxicity, meaning the substance is toxic to cartilage cells. Preclinical studies have provided robust evidence that steroids exert dose-dependent deleterious effects on cartilage morphology, histology, and viability. Simply put, the higher the dose of the steroid, the more damage it can cause to the cartilage. Among the different types, dexamethasone and triamcinolone appear to be the least toxic, but the risk remains.

This isn’t just a finding in lab studies. High-level clinical trials support these concerns. A pivotal study published in JAMA in 2017 was a two-year, randomized, placebo-controlled trial comparing injections of triamcinolone to saline in patients with knee OA (McAlindon et al., 2017). Patients received an injection every 12 weeks. The findings were startling:

There was no significant difference in pain relief between the steroid group and the placebo (saline) group over the two years.
The group receiving repeated steroid injections experienced significantly greater cartilage volume loss compared to the placebo group.

Another powerful retrospective review of over 49,000 patients, published in 2019, found that patients who received even one to three steroid injections (for various hip or knee conditions, not just OA) had a twofold greater risk of needing a knee replacement at the five-year mark (Kompel et al., 2019). The study also revealed a dose-dependent relationship: the risk of total knee arthroplasty (TKA) increased with each subsequent injection.

In my clinical practice at ChiroMed, I’ve observed this pattern. Patients who have received multiple steroid injections over the years often present with more advanced degenerative changes on their imaging than their symptom history might suggest. This is why there is a strong call within the medical community to find safer alternatives. While a single, first-time injection for an acute flare might seem reasonable, we must ask ourselves if we are sacrificing long-term joint health for short-term relief.

Ketorolac: A Safer, Fast-Acting Alternative for Knee Flares

If we want to avoid the chondrotoxic effects of steroids but still provide rapid relief for a patient like the one we discussed, where do we turn? I want to present an excellent alternative: ketorolac.

Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that can be injected directly into the joint. Its mechanism of action is different from and safer than corticosteroids:

As a COX-1 and COX-2 inhibitor, it blocks prostaglandin production, which is a key mediator of inflammation and pain sensitization.
Delivering it locally via injection achieves a high concentration in the synovial fluid, providing potent anti-inflammatory effects with minimal systemic exposure compared with oral NSAIDs.
Crucially, ketorolac provides anti-inflammatory and analgesic effects without the immunosuppressive and gene-expression-altering effects of steroids.

Most importantly, preclinical models have not shown the deleterious structural effects on cartilage that we see with steroids. Its onset of action is similar, within a few days, and its efficacy often lasts for a few months.

A 2021 systematic review and meta-analysis confirmed that, for knee and hip OA, an intra-articular ketorolac injection provides pain and functional improvements similar to those of corticosteroids from one week to three months post-injection, with minimal adverse events (Saltzman et al., 2021). Our own research has echoed these findings. In a study we conducted on hip pathologies, including OA, we found a trend toward greater pain improvement in the ketorolac group, which was statistically significant for the OA patients. The onset of relief was rapid (around 3 days for ketorolac), and the duration was comparable to that of steroids.

Therefore, ketorolac stands out as a fantastic steroid-sparing option. It addresses the same goal—rapid relief from an inflammatory flare—without the known cartilage toxicity. However, we must still be cautious and avoid its use in patients with contraindications to NSAIDs, such as a history of gastrointestinal ulcers, severe cardiac or kidney disease, or those on anticoagulants.

Hyaluronic Acid for Long-Term Joint Health

What if our patient doesn’t have an acute flare? What if they present with more chronic, persistent pain and want to improve the long-term health of their joint? This is where we shift our focus from just putting out the fire of inflammation to improving the joint’s structural environment. A primary candidate for this goal is hyaluronic acid (HA), also known as viscosupplementation.

The core concept behind HA injections is to augment the natural viscoelastic properties of the synovial fluid. In an osteoarthritic joint, the natural endogenous HA is depleted and degraded. This reduces the fluid’s viscosity and lubricating properties. By supplementing it with an injection, we aim to:

Improve joint lubrication and shock absorption.
Modulate nociception (pain signaling) and inflammation.

HA works through several biological pathways. It binds to a receptor on synovial cells, CD44, which in turn helps modulate inflammation by decreasing inflammatory cytokines such as IL-1β and cartilage-degrading enzymes such as MMPs. It also appears to stimulate the joint’s own cells to produce more of their natural HA and may have direct chondroprotective effects.

Clinical evidence shows that HA leads to a small but statistically significant reduction in knee OA pain compared to placebo. A comprehensive review by Jevsevar et al. (2015) showed that the pain-relieving effects tend to peak around two months and can last for six months or longer. The treatment appears to be most effective in patients under 65, those with a higher BMI, more severe baseline symptoms, and lower radiographic severity.

It’s important to note that not all HA is created equal. Molecular weight matters. Basic science shows that high-molecular-weight HA has a more profound chondroprotective effect, a greater ability to reduce inflammation through the CD44 pathway, and is better at stimulating the body’s own HA production compared to low-molecular-weight formulations. This is a critical factor I consider when selecting a product for my patients.

Despite this evidence, there is no unified stance on HA. While many European societies accept its use, leading U.S. organizations like the American Academy of Orthopedic Surgeons (AAOS) generally discourage it, citing that the clinical benefit is not consistently large enough. As a result, many insurance companies no longer provide coverage, making it an out-of-pocket expense for many patients. While some studies suggest HA can delay the need for knee replacement surgery, it is not considered a true disease-modifying treatment. This leads us to the next logical step in our journey: biologics.

Platelet-Rich Plasma (PRP): A True Disease-Modifying Potential

If we are looking for an injection that can both treat pain effectively and potentially modify the disease process itself, the strongest evidence currently points to Platelet-Rich Plasma (PRP).

PRP is a concentrate of platelets derived from the patient’s own blood. These platelets are a reservoir of powerful growth factors and signaling molecules that orchestrate tissue healing. When injected into an osteoarthritic knee, PRP has multiple effects:

Modulates Inflammation: It influences key inflammatory pathways, such as NF-kappa B, shifting the joint environment from a pro-inflammatory (M1 macrophage) state to an anti-inflammatory and regenerative (M2 macrophage) state.
Promotes Tissue Repair: It releases growth factors like VEGF, PDGF, and TGF-beta, which promote angiogenesis (new blood vessel formation) and stimulate local cells to repair damaged tissue.
Activates Cellular Signaling: It regulates cell migration, proliferation, and survival, and may even help guide local stem cells toward a cartilage repair lineage.

Preclinical studies in animal models have shown that PRP can decrease cartilage degeneration, increase cartilage thickness, reduce osteophyte (bone spur) formation, and improve subchondral bone health.

The clinical evidence for PRP in knee OA is vast and robust. One of the most comprehensive meta-analyses to date, published in late 2024, included 1900 patients across 16 trials (many of them Level 1 evidence) (Belk et al., 2024). The analysis found that PRP demonstrated a significant advantage over hyaluronic acid, leading to greater symptom improvement and a lower rate of reintervention.

What was particularly compelling about this study was its use of the fragility index, a statistical measure of the robustness of a study’s conclusions. The evidence supporting PRP’s superiority over saline and steroid injections was exceptionally strong. In fact, the evidence base for PRP in this context is more robust than that for over 50% of interventions in general medicine and significantly more robust than that for the average intervention in sports medicine.

A crucial question for any OA treatment is whether it can delay surgery. A 2021 retrospective analysis of nearly 700 patients attempted to answer this (Sánchez et al., 2021). The results were profound:

85% of patients did not undergo a total knee replacement during the five-year follow-up period.
For those who did eventually need surgery, the median delay was 5.3 years.
Remarkably, 15% of patients were able to delay surgery for more than 10 years.

The Critical Role of Dose in PRP for Regenerative Medicine

The journey with PRP has had its ups and downs. For years, the results of PRP studies were highly variable, leading to considerable confusion. Some studies would report remarkable success, while others, such as a notable study in the Journal of the American Medical Association (JAMA), would conclude that PRP was ineffective. This left us with a critical question: why the discrepancy? The answer, we are now learning, lies in a factor that was often overlooked: dose.

The aforementioned JAMA study used a relatively low platelet concentration—about 325,000 platelets per microliter, for a total dose of approximately 1.6 billion platelets. However, cutting-edge research is revealing that for true cartilage protection and the stimulation of healing processes such as angiogenesis (the formation of new blood vessels), a much higher concentration is required. The target we now aim for is 1.5 to 2 million platelets per microliter.

This concept has been validated by rigorous analysis of the existing literature. A systematic review my colleagues and I analyzed found a stark difference in outcomes based on dosage:

Studies with Positive Outcomes: Used an average total dose of 5.5 billion platelets.
Studies with Negative Outcomes: Used an average total dose of only 2.2 billion platelets.

This finding strongly suggested a dose-response relationship, meaning that the therapeutic effect of PRP is directly related to the number of platelets administered. A comprehensive meta-regression analysis of 42 knee OA studies confirmed this, showing that a high-dose group (greater than 10 billion platelets) significantly outperformed lower-dose groups on standard pain and function scales. The takeaway is clear: not all PRP is created equal. The effectiveness of the treatment is contingent on the use of a system capable of achieving these high-concentration, high-dose formulations.

PRP vs. Hyaluronic Acid (HA) for Osteoarthritis

Let’s return to a common clinical scenario: a patient with knee OA wants a healthier, long-term solution. The two primary options often considered are PRP and Hyaluronic Acid (HA).

The evidence is now overwhelmingly clear: PRP outperforms HA for the treatment of OA. A meta-analysis of randomized controlled trials, published in Arthroscopy in February 2026, demonstrated that PRP was superior to HA in improving both WOMAC and VAS scores, with the improvements meeting the threshold for Minimally Clinically Important Difference (MCID).

But does this mean HA has no role? Not necessarily. An exciting area of research is the combination of PRP and HA. The rationale is that their mechanisms are complementary:

PRP: Works on a biologic level, delivering a high concentration of growth factors that reduce inflammation and stimulate matrix synthesis.
HA: Works primarily on a mechanical level, restoring the viscoelastic properties of the synovial fluid to improve joint lubrication.

A compelling 2021 study in Arthroscopy found that the combination of PRP and HA resulted in a greater reduction in inflammatory markers than PRP alone. Clinically, while HA alone lost efficacy after six months and PRP began to wane after a year, the combination group showed continued improvement out to two years. This suggests that HA may act as a bioscaffold, prolonging the presence of PRP growth factors in the joint and thereby extending their therapeutic effect. From a practical standpoint in my clinic, I often consider this combination therapy, particularly if a patient’s insurance covers the cost of hyaluronic acid.

Comparative Look at Knee Injectables for OA

To summarize the key differences, let’s break down how each injectable option functions within the joint:

Mechanism	Platelet-Rich Plasma (PRP)	Corticosteroids	Hyaluronic Acid (HA)	Ketorolac (Toradol)
Chondroprotection	Excellent: Stimulates chondrocytes and protects cartilage.	Catabolic: Harmful to cartilage cells with repeated use.	Mild: Some protective effects.	None: No direct effect on cartilage.
Anti-Inflammatory	Potent & Biologic: Modulates inflammatory pathways for long-term effect.	Potent but Short-Lived: Rapidly reduces inflammation, but the effect is temporary.	Mild: Modest anti-inflammatory action.	Potent: Blocks COX enzymes for rapid pain and inflammation relief.
Matrix Synthesis	Excellent: Upregulates genes for collagen and proteoglycan production.	Inhibitory: Suppresses the synthesis of new cartilage matrix.	Modest: Small increase in matrix synthesis.	None: No benefit to matrix synthesis.
Viscoelastic Support	None: Does not improve joint lubrication.	None: No mechanical benefit.	Excellent: The primary mechanism is restoring joint fluid viscosity.	None: No mechanical benefit.
Longevity of Effect	Longest: Months to years.	Short: Weeks.	Moderate: 4 to 6 months.	Short: Weeks to a month.

The Role of Integrative Chiropractic Care

As a practitioner who integrates chiropractic care into my treatment plans, I see these advanced injections as powerful tools that work synergistically with our philosophy. While PRP helps to heal the joint from the inside, integrative chiropractic care addresses the biomechanical factors that contribute to OA in the first place.

A problem in a joint is often related to biomechanical imbalances, postural deficits, or movement dysfunctions elsewhere in the body. Chiropractic care is essential for:

Restoring Proper Biomechanics: Through spinal and extremity adjustments, we correct joint misalignments that place abnormal stress on the knee, addressing the root cause of the overload. Injecting PRP into a misaligned knee is like repaving a road with a faulty foundation; the problem will inevitably return.
Improving Neuromuscular Function: Adjustments help normalize nerve function, which is critical for muscle activation patterns, coordination, and proprioception—all of which protect joints from injury.
Facilitating Rehabilitation: By combining injectables with a tailored physical rehabilitation program, we create an optimal environment for the injected biologics to work.

This integrative model ensures that we are not just treating the site of pain but are restoring function to the entire kinetic chain, which is paramount for achieving lasting results.

Conclusion: A Personalized, Evidence-Based Approach

So, returning to our 60-year-old patient with the wedding next week, what is the best choice?

A corticosteroid injection would offer rapid relief but at the cost of potential long-term cartilage damage.
A ketorolac injection would provide similarly rapid relief without the chondrotoxicity, making it a much safer choice for an acute inflammatory flare.
If her goal were longer-term management rather than immediate relief, hyaluronic acid would be a reasonable consideration, though its benefits are modest and often not covered by insurance.
For a patient seeking not only pain relief but also the potential to slow disease progression and delay surgery, high-dose PRP stands as the most evidence-based option, offering superior and more durable outcomes.

In my practice, the journey doesn’t end with an injection. It’s about creating a comprehensive, personalized treatment plan. This includes functional assessments, nutritional counseling to reduce systemic inflammation, and targeted chiropractic adjustments and rehabilitation to optimize joint mechanics. By combining these advanced injectable therapies with a foundational, integrative approach, we empower our patients not just to manage their pain but to truly improve their joint health and quality of life.

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

References

SEO Tags: knee osteoarthritis, knee pain, intra-articular injections, corticosteroid, chondrotoxicity, ketorolac, hyaluronic acid, viscosupplementation, PRP, platelet-rich plasma, regenerative medicine, integrative chiropractic, Dr. Alexander Jimenez, knee OA treatment, PRP dose, high-dose PRP, non-surgical knee treatment, evidence-based medicine, functional medicine, joint health, cartilage protection

Tag: functional medicine

Abstract: A New Paradigm in Metabolic Health

Rethinking Diabetes: Beyond Glucose-Centric Care

Pillars of Modern Diabetes Management

Clinical Case Study: The Challenge of “Over-Basalization”

The Problem: Over-Basalized and Still Not at Goal

Understanding GLP-1 Receptor Agonists: The Incretin Effect

Mechanisms of Action: More Than Just Blood Sugar Control

The “Ominous Octet” and the Power of GLP-1s

Choosing the Right GLP-1 Agonist: A Comparative Look

Cardiovascular Outcomes Trials (CVOTs): The Game-Changer

How Professional Guidelines Position GLP-1 Agonists

Balancing Body and Metabolism- Video

Navigating the Switch: A Guide to Changing GLP-1 Agonists

The Expanding Universe of GLP-1 Receptor Agonists

Metabolically Associated Steatotic Liver Disease (MASLD)

Expanding Indications: Beyond Diabetes

Cravings, Compulsive Behaviors, and Addiction

PCOS, Fertility, and the “Ozempic Babies” Phenomenon

Other Investigational Uses

The Role of Integrative Chiropractic Care

Safety, Side Effects, and Practical Recommendations

Common GI Side Effects

Important Safety Issues

Black Box Warning: Thyroid C-Cell Tumors

Final Thoughts: A New Hope for Patients

References

Abstract

Why GLP-1 Therapies Matter Now for Obesity and Cardiometabolic Health

Key Terminology and Why These Hormones Matter

Mechanisms of Action: The Physiology Behind the Benefits

From Lizard Peptides to Long-Acting Analogs: The Trajectory of Innovation

Evidence Highlights: What the Strongest Trials Show

Safety Profile: Adverse Effects and How to Mitigate Them

Dosing Strategies: Why “Start Low, Go Slow” Works

Perioperative Care: GLP-1 Use and Aspiration Risk

Major Drug Interactions Clinicians Must Check

Public Health Safety: Counterfeit and Unregulated Online Sales

FDA Safety Monitoring: Suicidal Ideation Reports Under Evaluation

Long-Term Use: Why Continuing Therapy Matters

Discontinuation: Why Patients Stop and How to Prevent It

Guideline Alignment: Where GLP-1 Therapies Fit

Personalizing Therapy: Matching the Agent to the Patient

Integrative Chiropractic Care: Amplifying Outcomes and Preserving Function

Clinical Observations from My Practice

Case Study: Re-Initiating Semaglutide Safely After an Interruption

Eating Right to Feel Better- Video

Integrative Nutrition: The MEAL Framework

Movement and Resistance Training: Protecting Lean Mass and Metabolic Rate

Practical Clinical Pearls: What Works Best

Common Pitfalls to Avoid

Putting It All Together: A Patient-Centered, Integrative Roadmap

References

Abstract

What Is a Platelet and Why Does It Matter?

The Problem of Variability in PRP Preparations

The Evidence for PRP: A Growing Body of Research

How We Create Your Personalized PRP Treatment in Our Clinic

The Critical Concept of PRP Dosing

Dosing for Tendons and Soft Tissues

How Patient Age Impacts Dosing

Dosing for Knee Osteoarthritis (OA)

Beyond Platelets: The Role of White and Red Blood Cells

The Integral Role of Chiropractic Care and Rehabilitation

Key Takeaways for Patients and Practitioners

References

Abstract

Why We Seek Alternatives to Traditional Approaches

Understanding the Tools: Corticosteroids, HA, and PRP

Corticosteroids: The Double-Edged Sword

Hyaluronic Acid (HA): The Joint Lubricant

Platelet-Rich Plasma (PRP): Harnessing the Body’s Healing Power

The Evidence: Comparing PRP, Steroids, and HA

PRP vs. Corticosteroids

PRP vs. Hyaluronic Acid (HA)

Summary of Evidence Table

Making the Right Choice: A Patient-Centered Approach

The Crucial Role of Integrative Chiropractic Care

Final Thoughts

References